

WEST Search History

DATE: Tuesday, May 18, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L1	collier.in.	864
<input type="checkbox"/>	L2	L1 and anthrax	4
<input type="checkbox"/>	L3	poreforming.clm. or pore-forming.clm. or poreformation.clm. or pore-formation.clm. or (pore.clm. and anthrax.clm.)	316
<input type="checkbox"/>	L4	L3 and anthrax	6
<input type="checkbox"/>	L5	channelforming.clm. or channel-forming.clm. or channelformation.clm. or channel-formation.clm.	299
<input type="checkbox"/>	L6	L5 and anthrax	0
<input type="checkbox"/>	L7	channel near (forming or formation or producing or production)	25088
<input type="checkbox"/>	L8	L7 and anthrax	24
<input type="checkbox"/>	L9	L7 same anthrax	4

END OF SEARCH HISTORY

0024] "B moiety" means the component of a pore-forming A-B toxin which binds a specific host cell-surface receptor, interacts with the A moiety of the toxin, and aids in internalization of the A moiety into the cell. Many B moieties, such as PA, also form transmembrane pores.

WEST Search History

Hide Items	Restore	Clear	Cancel
------------	---------	-------	--------

DATE: Tuesday, May 18, 2004

Hide?	Set Name	Query	Hit Count
-------	----------	-------	-----------

DB=USPT; PLUR=YES; OP=AND

<input type="checkbox"/>	L1	6455673.pn.	1
<input type="checkbox"/>	L2	5917017.pn.	1

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)**End of Result Set**

L1: Entry 1 of 1

File: USPT

Sep 24, 2002

US-PAT-NO: 6455673

DOCUMENT-IDENTIFIER: US 6455673 B1

**** See image for Certificate of Correction ****

TITLE: Multi-mutant diphtheria toxin vaccines

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collier; R. John	Wellesley Hills	MA		

US-CL-CURRENT: 530/350; 424/136.1, 424/143.1, 424/150.1, 424/178.1, 424/183.1,
424/184.1, 424/185.1, 424/203.1, 424/236.1, 424/238.1, 424/239.1, 424/245.1,
435/29, 435/69.1, 435/69.7

CLAIMS:

What is claimed is:

1. An isolated polypeptide comprising a mutant diphtheria toxin C domain, a mutant diphtheria toxin T domain, and a mutant diphtheria toxin R domain, said C domain comprising a mutation in Glu148, said T domain comprising a mutation in Glu349, and said R domain comprising a mutation in one or both of Lys516 and Phe530 of wild-type diphtheria toxin.
2. The polypeptide of claim 1 in which the mutant C domain comprises the mutation Glu148Ser.
3. The polypeptide of claim 1 in which the mutant T domain comprises the mutation Glu349Lys.
4. The polypeptide of claim 1 in which the mutant R domain comprises the mutation Lys516Ala or the mutation Phe530Ala or both.
5. A preparation of the isolated polypeptide of claim 1 comprising a carrier.
6. The polypeptide of claim 1 in which the C domain comprises the mutation Glu148Ser, the T Domain comprises the mutation Glu349Lys, and the R domain comprises the mutations Lys516Ala and Phe530Ala.
7. A composition comprising the polypeptide of claim 1 and an adjuvant.

[First Hit](#) [Fwd Refs](#)**End of Result Set**☐

L2: Entry 1 of 1

File: USPT

Jun 29, 1999

US-PAT-NO: 5917017

DOCUMENT-IDENTIFIER: US 5917017 A

TITLE: Diphtheria toxin vaccines bearing a mutated R domain

DATE-ISSUED: June 29, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collier; R. John	Wellesley Hills	MA		
Shen; Wei Hai	Boston	MA		
Eisenberg; David	Los Angeles	CA		
Choe; Seunghyon	Solana Beach	CA		

US-CL-CURRENT: 530/350; 424/183.1, 424/184.1, 424/185.1, 424/203.1, 424/236.1,
424/239.1, 424/245.1, 435/29, 435/69.1, 435/69.7

CLAIMS:

What is claimed is:

1. A substantially pure polypeptide comprising a mutant diphtheria toxin R domain, said R domain comprising a mutation in at least one or more residues from the group consisting of Lys 516, Lys 526, Phe 530, and Lys 534 of wild-type diphtheria toxin, said polypeptide binds sensitive cells with less affinity than wild-type diphtheria toxin and forms an immune complex with an antibody which specifically recognizes the R domain of wild-type diphtheria toxin.
2. The polypeptide of claim 1, in which at least one or more residues from the group consisting of Lys 516, Lys 526, and Lys 534 is replaced by either Cys or Phe.
3. The polypeptide of claim 1, in which said Phe 530 is substituted by any one of the group consisting of Glu, Lys, or Gln.
4. The polypeptide of any one of claims 1-3, said polypeptide further comprising at least part of diphtheria toxin fragment B, wherein said fragment B lacks the segment between amino acids 379-535, inclusively, of wild-type diphtheria toxin.
5. The polypeptide of any one of claims 1-3, said polypeptide comprising at least part of diphtheria toxin fragment A.
6. The polypeptide of claim 4, said polypeptide comprising at least part of diphtheria toxin fragment A.

7. The polypeptide of claim 4, said polypeptide comprising all of diphtheria toxin fragment A.
8. A vaccine comprising the polypeptide of any one of claims 1-3 and a physiologically acceptable carrier.
9. A vaccine comprising the polypeptide of claim 4 and a physiologically acceptable carrier.
10. A vaccine comprising the polypeptide of claim 5 and a physiologically acceptable carrier.
11. A live vaccine strain comprising a cell comprising DNA encoding the polypeptide of claim 1, said cell being any one of a *B. subtilis*, BCG, *Salmonella* sp., *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.
12. A live vaccine strain comprising a cell comprising DNA encoding the polypeptide of claim 4, said cell being any one of a *B. subtilis*, BCG, *Salmonella* sp., *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.
13. A live vaccine strain comprising a cell comprising DNA encoding the RolyDeptide of claim 5, said cell being any one of a *B. subtilis*, BCG, *Salmonella* sp., *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.
14. A method of preparing a polypeptide comprising:
providing the cell of claim 11,
growing said cell in a medium to form a population of cells that express said polypeptide, and
obtaining said polypeptide from said population of cells or said medium.
15. A method of preparing a polypeptide comprising:
providing the cell of claim 12,
growing said cell in a medium to form a population of cells that express said polypeptide, and
obtaining said polypeptide from said population of cells or said medium.
16. A method of preparing a polypeptide comprising:
providing the cell of claim 13,
growing said cell in a medium to form a population of cells that express said polypeptide, and
obtaining said polypeptide from said population of cells or said medium.
17. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 8 into said mammal.

18. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 9 into said mammal.
19. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 10 into said mammal.
20. The method of claim 17, wherein said mammal is a human.
21. The method of claim 18, wherein said mammal is a human.
22. The method of claim 19, wherein said mammal is a human.
23. A fusion polypeptide comprising the polypeptide of any one of claims 1-3, linked by a peptide bond to a second polypeptide.
24. A fusion polypeptide comprising the polypeptide of claim 4 linked by a peptide bond to a second polypeptide.
25. A fusion polypeptide comprising the polypeptide of claim 5 linked by a peptide bond to a second polypeptide.
26. A substantially pure polypeptide comprising a mutant diphtheria toxin R domain, said mutant R domain having the sequence of the wild-type diphtheria toxin R-domain, in which Ala is substituted for Lys 516.
27. A substantially pure polypeptide comprising a mutant diphtheria toxin R domain, said mutant R domain having the sequence of the wild-type diphtheria toxin R-domain, in which Ala is substituted for Phe 530.

[0013] In one desirable embodiment of the fourth aspect, the mutant PA has an amino acid sequence that is at least 80%, 90%, 95%, or 98% identical to a naturally-occurring PA protein (such as SEQ ID No. 21; FIG. 13) and that has one of the following alterations: K397D+D425K double mutation, .DELTA.D2L2 (in which residues 302-325 of PA are deleted), K395D+K397D+D425K+D426K quadruple mutation, D425K, F427A, K397D+D425K+F427A triple mutation, F427A+.DELTA.D2L2 double mutation, K397D+F427A+.DELTA.D2L2 triple mutation, K397D+D425K+F427A+.DELTA.D2L2 quadruple mutation, F427D, or F427K. In another desirable embodiment, the PA mutant has a sequence identical to any of SEQ ID Nos.: 8-18 (Table 1). In another embodiment, amino acid 395, 397, 425, 426, or a combination thereof, in naturally-occurring PA is mutated. In yet another embodiment, a residue in domain 2 of PA is mutated. In another desirable embodiment, the mutant has a deletion of at least 5, at least 10, or at least 20 amino acids of the residues in the D2L2 loop of PA or in the corresponding region of a B moiety of another pore-forming binary A-B toxin. The mutant can have a deletion of all or part of the D2L2 loop and a deletion of amino acids that are N-.DELTA. or C-terminal to the loop. Still other desirable mutant B moieties include *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis* toxins that have one or more of the alterations listed in Table 6 or that have a mutation in the region that corresponds to domain 2 of PA. Fragments of the above mutant B moieties, in which the fragment has a reduced pore-forming ability compared to a naturally-occurring B moiety and inhibits the pore-forming ability of a naturally-occurring B moiety, are included in the invention. Fusion proteins having a mutant B moiety or a fragment of a mutant B moiety covalently bound to another polypeptide or protein are included.

0033] "Fragment" means polypeptide having a region of consecutive amino acids that is identical to the corresponding region in a PA mutant. The fragment has either a reduced ability to form pores or translocate toxins compared to naturally-occurring PA. The fragment may also inhibit the pore-forming ability of naturally-occurring PA. This decrease in pore formation or toxin translocation is positively correlated with, and could be predicted by, a decrease in activity in the cell surface translocation, LFnDTA toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LFnDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. In one desirable embodiment, the decrease in pore formation or translocation of EF or LF is at least 20% relative to naturally-occurring PA₆₃. More desirably, the decrease is at least 40%, and most desirably, the decrease is at least 80%. The inhibition of the pore-forming ability of naturally-occurring PA is positively correlated with, and could be predicted by, a decrease in activity in an assay described above using an equimolar mixture of naturally-occurring PA and a PA fragment compared to using naturally-occurring PA alone. In one desirable embodiment, the decrease is at least 20, 40, 60, 80, or 99% compared to the activity using only naturally-occurring PA. Desirably, the fragment is immunogenic and induces the production of protective antibodies against naturally-occurring PA. In another desirable embodiment, the administration of the fragment to a mammal, as described in Example 9, prevents or diminishes an anthrax infection for a period of at least 1 month, more desirably 3 months, or most desirably 6 months. Examples of possible fragments include the C-terminal 63 kDA tryptic fragment of a PA mutant or a PA mutant having a deletion of amino acids that form the transmembrane pore.

Cell Binding
Receptor binding

Cell-type Specific
Binding

Cellular binding activity was demonstrated through structure-function and deletion analysis of wild type PA. PA binds specifically to a cell-surface receptor found on a wide variety of cell types (Leppla et al., in Bacterial Protein Toxins, pp. 111-112 (Fehrenbach et al., eds., 1988)). Structure-function experiments of protease-digested PA established that the carboxyl-terminus contains the receptor-binding domain (Novak et al., J. Biol. Chem., 267: 17186-17193 (1992)). Further deletion analysis of the carboxyl-terminus revealed that mutant PA proteins truncated by 3, 5, or 7 amino acids at the carboxyl-terminus had a 2- to 10-fold reduction in cell binding activity (Singh et al., J. Biol. Chem., 266: 15493-15497 (1991)). In addition, binding activity was lost upon deletion of 12 or 14 amino acids from the carboxyl-terminus (Singh, supra (1991))

[0009]

— lacks pore forming ability

[0012] inhibition of pore forming ability;

[0024] binds to specific host cell-

surface receptor

interacts with the H moiety of the toxin

and internalization of the H moiety into the cell;

Detailed Description Text (27):

Protective antigen was expressed in *B. anthracis* from the expression vector pYS5 and purified by established procedures (Singh et al., J. Biol. Chem. 264: 19103-19107 (1989); Leppla, in Methods in Enzymology, vol. 165, pp. 103-116 (Harshman ed., 1988). Mutant PA molecules PA CFD and PA--D were constructed by site-directed mutagenesis and have been previously described (Singh et al., J. Biol. Chem. 269: 29039-29046 (1994)). The mutant PA molecules were used as negative controls in Example 3.

First Hit

L2: Entry 3 of 4

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039588
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039588 A1

TITLE: Compounds and methods for the treatment and prevention of bacterial infection infection

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Collier, R. John</u>	Wellesley	MA	US	
Sellman, Bret R.	Rochester	NY	US	

APPL-NO: 09/ 848909 [PALM]
DATE FILED: May 4, 2001

RELATED-US-APPL-DATA:

Application is a non-provisional-of-provisional application 60/201800, filed May 4, 2000,

INT-CL: [07] A61 K 39/07, C12 N 9/54
US-CL-PUBLISHED: 424/246.1; 424/236.1, 435/221
US-CL-CURRENT: 424/246.1; 424/236.1, 435/221

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.

GOVT-INTEREST:

[0002] This invention was funded by grants R37-AI22021 and 2T32-AI07410 from the National Institute of Health. The government may have certain rights in the invention.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from U.S. Provisional Application No. 60/201,800, filed May 4, 2000.

BACKGROUND OF THE INVENTION

[0003] In general, the invention features compounds and methods for the treatment

of bacterial infections, such as anthrax infection.

[0004] The etiologic agent of anthrax (*Bacillus anthracis*) is a potential threat as an agent of biowarfare or bioterrorism because exposure to aerosolized *B. anthracis* spores can be lethal to mammals, such as humans. The major virulence factors produced by this organism are the poly-D-glutamic acid capsule and anthrax toxin (ATx). Both the capsule and the toxin assist in colonization and immune evasion by the bacterium. ATx alone can cause death of the host. Vaccination against the toxin protects the host against infection.

[0005] Anthrax toxin is a member of the class of bacterial toxins termed A-B toxins. A-B toxins are composed of two moieties; the A moiety is the enzymic portion of the toxin that catalyzes the toxic effect upon a cytoplasmic target within a target cell. The B moiety binds to a cellular receptor and facilitates the translocation of the A moiety across the cell membrane into the cytoplasm of the cell.

[0006] The B moieties of A-B toxins from tetanus, botulinum, diphtheria and anthrax all form channels in membranes. It has been hypothesized that these channels might act as the conduit for the membrane translocation of the A moiety. The A and B moieties of anthrax toxin are secreted from the bacterial cell as distinct polypeptides. The A and B subunits of other A-B toxins are produced as single chain polypeptides or as separate chains that are assembled into oligomeric toxins before release from the bacteria. There are two alternative A subunits of anthrax toxin called edema factor (EF) and lethal factor (LF). Noncovalent complexes of EF or LF and the B subunit, protective antigen (PA), are called edema toxin and lethal toxin, respectively. PA facilitates the translocation of both EF and LF across membranes.

[0007] PA is secreted as an 83 kDa monomeric polypeptide. Monomeric PA binds to a mammalian cell surface receptor and is proteolytically cleaved. The C-terminal 63 kDa fragment (PA63) remains bound to the cell and the N-terminal 20 kDa (PA20) dissociates from PA63. This proteolytic cleavage and subsequent dissociation of PA20 confer two new properties on PA63: (1) the ability to oligomerize into a ring-shaped heptameric SDS-dissociable structure termed prepore and (2) the ability to bind EF and LF. Oligomers containing PA63-EF, PA63-LF, or a combination of PA63-EF and PA63-LF are endocytosed and trafficked to an acidic compartment, where the PA63 prepore inserts into the membrane and forms a pore. During or after pore formation, EF and LF are translocated across the endosomal membrane into the cytoplasm. EF is a calmodulin-dependent adenylate cyclase which may protect the bacteria from destruction by phagocytes. LF is a metalloprotease that can kill macrophages or, at lower concentrations, induce macrophages to overproduce cytokines, possibly resulting in death of the host.

[0008] A crucial step in this intoxication pathway is pore formation by PA. Low pH serves as the trigger for conversion of the PA63 prepore to the pore. This conversion is accompanied by a transformation of the oligomer from an SDS-dissociable to an SDS-resistant state and formation of a transmembrane 14-strand .beta.-barrel. These steps are believed to be necessary for translocation of EF and LF across the endosomal membrane and, thus, toxin action.

SUMMARY OF THE INVENTION

[0009] In a first aspect, the invention provides a B moiety of a pore-forming binary A-B toxin. The B moiety has a mutation that results in inhibition of its pore-forming ability. In one desirable embodiment, this mutation results in inhibition of the pore-forming ability of the protein in vivo. In another desirable embodiment, the mutant B moiety lacks pore-forming ability in vitro and/or in vivo.

In yet another desirable embodiment, the B moiety is anthrax protective antigen (PA). In yet another desirable embodiment, the PA mutant has an amino acid sequence that is at least 80%, 90%, 95% or 98% identical to a naturally-occurring PA protein (such as SEQ ID No.: 21; FIG. 13) and that has one of the following alterations: K397A, K397D, K397C, K397Q, D425A, D425N, D425E, D425K, F427A, K397+D425K double mutation, K395D+K397D+D425K+D426K quadruple mutation, .DELTA.D2L2 PA (deletion of residues 302-325), K397D+D425K+F427A triple mutation, F427A+.DELTA.D2L2 double mutation, K397D+F427A+.DELTA.D2L2 triple mutation, K397D+D425K+F427A+.DELTA.D2L2 quadruple mutation, F427D, or F427K. In another desirable embodiment, the PA mutant has a sequence identical to any of SEQ ID Nos.: 1-18 (Table 1). Other desirable PA mutants include PA mutants in which residue 397 is any amino acid except lysine (SEQ ID No.: 19), PA mutants in which residue 425 is any amino acid except aspartic acid (SEQ ID No.: 20), PA mutants in which residue 427 is any amino acid except phenylalanine (SEQ ID No.: 23), and PA mutants that have a mutation in domain 2 (residues 259-487). Still other desirable mutant B moieties include *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis* toxins that have one or more of the alterations listed in Table 6 or that have a mutation in the region that corresponds to domain 2 of PA. Fragments of the above mutant B moieties, in which the fragment has a reduced pore-forming ability compared to a naturally-occurring B moiety of the corresponding toxin, are also included in the invention. Fusion proteins having a mutant B moiety of the invention or a fragment of such a mutant B moiety covalently bound to another polypeptide or protein are also included. In one embodiment, specifically excluded from this aspect is the deletion of amino acids 302-325 (D2L2 loop) of PA.

[0010] In a second aspect, the invention features a vaccine composition having a mutant B moiety of the first aspect, or a fragment thereof, in a pharmaceutically acceptable carrier. In a desirable embodiment, the vaccine can be inactivated by chemical or physical means. In one embodiment, specifically excluded from this aspect is a vaccine having .DELTA.D2L2 PA as its sole mutant B moiety.

[0011] In a third aspect, the invention features a method of preventing or treating bacterial infection in a mammal, such as a human. This method includes administering the vaccine of the second aspect to the mammal. In one desirable embodiment, the vaccine is administered with a pharmaceutically suitable carrier or an adjuvant. The vaccine can be administered orally, intramuscularly, intravenously, subcutaneously, by inhalation, or by any other route sufficient to provide a dose adequate to prevent or treat a bacterial infection. In another desirable embodiment, a vaccine that includes a mutant anthrax protective antigen is administered for the prevention or treatment of anthrax infection. In one embodiment, specifically excluded from this aspect is a method that involves administration of a vaccine having .DELTA.D2L2 PA as its sole mutant B moiety and that does not involve administration of another vaccine having another mutant B moiety.

[0012] In a fourth aspect, the invention provides a mutant B moiety of a pore-forming binary A-B toxin. The mutant B moiety has a mutation that results in inhibition of its pore-forming ability. The mutant B moiety also inhibits the pore-forming ability of a naturally-occurring B moiety of the corresponding toxin in vitro and/or in vivo. In one desirable embodiment, this mutation results in inhibition of the pore-forming ability of the protein in vivo. In another desirable embodiment, the mutant B moiety lacks pore-forming ability in vitro and/or in vivo. In yet another desirable embodiment, the B moiety is anthrax protective antigen (PA). The mutant B moiety may bind the A moiety of the corresponding toxin. For example, a PA mutant may bind the lethal factor or edema factor A moieties. The mutant B moiety may compete with a naturally-occurring B moiety for binding to a receptor on the surface of a mammalian cell. The mutant B moiety may also bind a naturally-occurring B moiety of the corresponding toxin. Such a mutant may oligomerize with a naturally-occurring B moiety to form a complex that has reduced

ability to form a pore. In one desirable embodiment, the complex lacks the ability to form a pore and to translocate an A moiety (e.g., EF or LF) across the membrane into the host cell cytoplasm.

[0013] In one desirable embodiment of the fourth aspect, the mutant PA has an amino acid sequence that is at least 80%, 90%, 95%, or 98% identical to a naturally-occurring PA protein (such as SEQ ID No. 21; FIG. 13) and that has one of the following alterations: K397D+D425K double mutation, .DELTA.D2L2 (in which residues 302-325 of PA are deleted), K395D+K397D+D425K+D426K quadruple mutation, D425K, F427A, K397D+D425K+F427A triple mutation, F427A+.DELTA.D2L2 double mutation, K397D+F427A+.DELTA.D2L2 triple mutation, K397D+D425K+F427A+.DELTA.D2L2 quadruple mutation, F427D, or F427K. In another desirable embodiment, the PA mutant has a sequence identical to any of SEQ ID Nos.: 8-18 (Table 1). In another embodiment, amino acid 395, 397, 425, 426, or a combination thereof, in naturally-occurring PA is mutated. In yet another embodiment, a residue in domain 2 of PA is mutated. In another desirable embodiment, the mutant has a deletion of at least 5, at least 10, or at least 20 amino acids of the residues in the D2L2 loop of PA or in the corresponding region of a B moiety of another pore-forming binary A-B toxin. The mutant can have a deletion of all or part of the D2L2 loop and a deletion of amino acids that are N-.DELTA. or C-terminal to the loop. Still other desirable mutant B moieties include *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *botulinum*, *Bacillus cereus*, or *B. thuringiensis* toxins that have one or more of the alterations listed in Table 6 or that have a mutation in the region that corresponds to domain 2 of PA. Fragments of the above mutant B moieties, in which the fragment has a reduced pore-forming ability compared to a naturally-occurring B moiety and inhibits the pore-forming ability of a naturally-occurring B moiety, are included in the invention. Fusion proteins having a mutant B moiety or a fragment of of a mutant B moiety covalently bound to another polypeptide or protein are included.

[0014] In a fifth aspect, the invention features a method of preventing or treating bacterial infection in a mammal, such as a human. This method includes administering administering a mutant B moiety of the fourth aspect, or a fragment thereof, that inhibits the pore-forming ability of a naturally-occurring B moiety to the mammal. In one embodiment, a PA mutant of the fourth aspect or a fragment thereof is administered to prevent or treat anthrax infection in mammals that have been exposed exposed to *B. anthracis* spores. In another embodiment, the protein is administered prophylactically. In one desirable embodiment, the mutant B moiety is administered with a pharmaceutically suitable carrier. The mutant may be administered orally, intramuscularly, intravenously, subcutaneously, by inhalation, or by any other route sufficient to provide a dose adequate to prevent or treat an anthrax infection. In one embodiment, the method also includes administering an anti-B moiety antibody, such as an antibody that binds a naturally-occurring B moiety but not the dominant negative mutant B moiety, to the mammal. In one particular embodiment, the antibody binds a naturally-occurring PA but not the dominant negative PA mutant.

[0015] In a sixth aspect, the invention features a nucleic acid encoding a mutant B moiety (e.g., a PA mutant) of the first or fourth aspects.

[0016] In a seventh aspect, the invention features a vector having the nucleic acid of the sixth aspect.

[0017] In an eighth aspect, the invention features a purified antibody that specifically binds a naturally-occurring PA or a PA mutant protein listed in Table 1. In one embodiment, the antibody binds to the D2L2 loop, K397, D425, D426, or F427 of a PA protein. The antibody may be a monoclonal or polyclonal antibody. In a related aspect, the invention features a purified antibody that specifically binds a naturally-occurring B moiety of a pore-forming binary A-B toxin with greater

affinity than it binds a B moiety of the present invention from the corresponding toxin. In another related aspect, the invention features a purified antibody that specifically binds a B moiety of the present invention with greater affinity than it it binds a naturally-occurring B moiety of the corresponding toxin.

[0018] In one embodiment of the first or fourth aspects, specifically excluded are those PA molecules having as their sole alteration, a mutation to cysteine of a residue located in the hydrophilic face of a transmembrane pore. In another embodiment of these aspects, PA molecules having as their sole alteration a mutation mutation in an amino acid in the hydrophilic face of a transmembrane pore are specifically excluded. In a embodiment, specifically excluded from the first or fourth aspects are those PA molecules having as their sole alteration, a mutation in in Glu302, His304, Asn306, Glu308, His310, Ser312, Phe313, Phe314, Asp315, Gly317, Ser319, Ser321, Gly323, or Ser325 in naturally-occurring PA. In one embodiment of these aspects, PA molecules having as their sole alteration, a mutation in the amino amino acid sequence of the D2L2 loop are specifically excluded. In another embodiment, PA molecules having as their sole alteration a mutation or deletion in an amino acid that forms the transmembrane pore are specifically excluded. In yet another embodiment, specifically excluded from one of these aspects are PA molecules molecules having the C-terminal 63 kDA tryptic fragment (PA63) and having as their sole alteration a mutation in an amino acid that forms the transmembrane pore. In still another embodiment, specifically excluded is .DELTA.D2L2 PA. In various other embodiments, specifically excluded from one of these aspects are other pore-forming binary A-B toxins that have a mutation that corresponds to a specifically excluded PA mutation. In various embodiments of these aspects, the mutant B moiety binds a naturally-occurring B moiety from the same A-B toxin with a higher equilibrium constant (i.e., with greater affinity) than the naturally-occurring B-moiety binds other naturally-occurring molecules from the same A-B toxin. In desirable embodiments, the mutant PA protein binds naturally-occurring PA with at least 2, 5, 10, or 20 fold greater affinity than naturally-occurring PA binds other naturally-occurring PA molecules.

[0019] It should be understood that other pore-forming toxins, in addition to anthrax toxin, may be used in the compounds and methods of the invention. For example, pore-forming toxins, such as other A-B toxins, having mutations (e.g., point mutations or deletion mutations) that inhibit the pore-forming ability of the toxin or that inhibit the pore-forming ability of the naturally-occurring toxin are included in the invention. The pore-forming toxins with these mutants can be used in the vaccine compositions or methods of the invention to prevent or treat infection by the etiologic agent of the toxin. While not meant to limit the invention in any way, other A-B binary toxins; hetero-oligomeric toxins (AB5 toxins), such as cholera toxin; or single polypeptide A-B toxins, such as tetanus, botulinum, or diphtheria toxin can be used. Other toxins that can be used include .alpha.-hemolysin from Staphylococcus aureus, aerolysin from Aeromonas hydrophila, .alpha.-toxin from Clostridium septicum, and cytotoxin from Pseudomonas aeruginosa. The invention is also relevant to any other pore-forming toxin such as cholesterol dependent cytolysins, hexameric toxins, or heptameric toxins. Examples of hexameric and heptameric toxins include toxins that are related to the Staphylococcal .alpha.-toxin. In one embodiment, a deletion mutant of the VacA toxin from Helicobacter pylori is specifically excluded.

[0020] "Mutation" means an alteration in the nucleic acid sequence such that the amino acid sequence encoded by the nucleic acid sequence has at least one amino acid alteration from a naturally-occurring sequence. The mutation may, without limitation, be an insertion, deletion, frameshift mutation, or missense mutation.

[0021] "Pore-forming toxin" means a toxin which forms a transmembrane aqueous pore.

[0022] "Pore-forming A-B toxin" means a pore-forming toxin with two functional

moieties; one moiety (B) which forms a pore in a host cell barrier membrane, and the other (A) traverses the membrane barrier and enzymatically modifies specific intracellular substrates of a host cell.

[0023] "Pore-forming binary A-B toxin" means a pore-forming A-B toxin in which the A and B moieties of the pore-forming toxin inhabit separate proteins, and interact during the intoxication of host cells. An example of a binary toxin is anthrax toxin.

[0024] "B moiety" means the component of a pore-forming A-B toxin which binds a specific host cell-surface receptor, interacts with the A moiety of the toxin, and aids in internalization of the A moiety into the cell. Many B moieties, such as PA, also form transmembrane pores.

[0025] "Protective antigen (PA)" means a polypeptide having at least 60%, 70%, 80%, or 90%, of at least one of the biological activities of the anthrax PA polypeptide described herein. The polypeptide may be encoded by the PA gene that was reported by Vodkin et al. (Cell 34:693-697, 1983). The polypeptide can be identical to wild-type PA characterized by Miller et al. (Biochemistry 38(32):10432-10441, 1999) (SEQ ID No.: 21) or any naturally-occurring PA polypeptide from a strain of *Bacillus anthracis*. The PA polypeptide may be cloned and expressed in a heterologous host, such as *Escherichia coli* or *Bacillus subtilis*. It is understood that homologs and analogs have the characteristics of the anthrax PA described herein and may be used in the methods of the invention.

[0026] "PA63" means the carboxy-terminal portion that results from proteolytic cleavage of a 20 kDa N-terminal segment from the PA polypeptide. PA63 forms a heptameric prepore and binds the two alternative A moieties, edema factor (EF) and lethal factor (LF). The entire complex is trafficked to the endosome, where PA63 inserts into the membrane, forms a transmembrane pore, and translocates EF and LF into the host cell cytoplasm.

[0027] "Transmembrane pore" means a transmembrane aqueous channel. For example, the transmembrane pore can be a .beta.-barrel channel formed by alternating hydrophilic and hydrophobic residues of PA63 such that the hydrophobic residues form an exterior membrane-contiguous surface of the barrel, and the hydrophilic residues face an aqueous lumen of a pore that spans across the host cell membrane.

[0028] "Hydrophilic face of a transmembrane pore" means the amino acids of PA that face the aqueous lumen of a pore that spans across the host cell membrane.

[0029] "An amino acid that forms the transmembrane pore" means an amino acid of PA that is located in a .beta.-barrel channel of a transmembrane pore.

[0030] "D2L2 loop" means the amphipathic loop which connects strands 2.beta.2 and 2.beta.3 of PA polypeptide and PA63 polypeptide as described herein.

[0031] "Inhibits the pore-forming ability" means reduces the amount of pores formed in membranes or reduces the rate or amount of an A moiety (e.g., EF or LF) that is translocated into the host cell cytoplasm. This decrease in pore formation or toxin translocation is positively correlated with, and could be predicted by, a decrease in activity in the cell surface translocation, LFnDTA toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LFnDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. Additionally, this decreased activity can be correlated with a decrease in

toxicity due to the translocation of a toxic ligand into cells. In one desirable embodiment, the decrease in pore formation or translocation of an A moiety is at least 20%, more desirably at least 40%, and most desirably at least 80% relative to a naturally-occurring B moiety of the corresponding toxin. In another desirable embodiment, the decrease in pore formation or translocation of EF or LF by a PA mutant is at least 20%, more desirably at least 40%, and most desirably at least 80% relative to naturally-occurring PA63

[0032] "Lacks pore-forming ability" means does not form a significant amount of pores in membranes or does not transfer a significant amount of EF or LF into the host cell cytoplasm. This lack of significant pore-forming or toxin translocating activity is positively correlated with, and could be predicted by, a lack of significant activity in the cell surface translocation, LF_nDTA toxicity, or rubidium release assays described herein. In one desirable embodiment, the amount of pores formed or the amount of toxin translocated is less than 5 times the amount detected in a control assay without PA. More desirably, the amount is less than 2 times the amount in a control assay without PA.

[0033] "Fragment" means polypeptide having a region of consecutive amino acids that is identical to the corresponding region in a PA mutant. The fragment has either a reduced ability to form pores or translocate toxins compared to naturally-occurring PA. The fragment may also inhibit the pore-forming ability of naturally-occurring PA. This decrease in pore formation or toxin translocation is positively correlated with, and could be predicted by, a decrease in activity in the cell surface translocation, LF_nDTA toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LF_nDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. In one desirable embodiment, the decrease in pore formation or translocation of EF or LF is at least 20% relative to naturally-occurring PA63. More desirably, the decrease is at least 40%, and most desirably, the decrease is at least 80%. The inhibition of the pore-forming ability of naturally-occurring PA is positively correlated with, with, and could be predicted by, a decrease in activity in an assay described above using an equimolar mixture of naturally-occurring PA and a PA fragment compared to using naturally-occurring PA alone. In one desirable embodiment, the decrease is at least 20, 40, 60, 80, or 99% compared to the activity using only naturally-occurring occurring PA. Desirably, the fragment is immunogenic and induces the production of protective antibodies against naturally-occurring PA. In another desirable embodiment, the administration of the fragment to a mammal, as described in Example 9, prevents or diminishes an anthrax infection for a period of at least 1 month, more desirably 3 months, or most desirably 6 months. Examples of possible fragments include the C-terminal 63 kDA tryptic fragment of a PA mutant or a PA mutant having a deletion of amino acids that form the transmembrane pore.

[0034] By "purified antibody" is meant an antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Desirably, the preparation is at least 75%, more desirably 90%, and most desirably at least 99%, by weight, antibody. A purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

[0035] By "specifically binds" is meant an antibody that recognizes and binds to, for example, wild-type PA or a PA mutant but does not substantially recognize and bind to other non-PA molecules in a sample, e.g., a biological sample, that naturally includes protein. A desirable antibody specifically binds any of the PA mutants # 1-18 in Table 1. Other desirable antibodies bind wild-type PA with at least 2, 5, 10, or 20 fold greater affinity than they bind one or more of the PA

mutants in Table 1.

[0036] Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0037] Other features and advantages of the invention will be apparent from the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0038] FIG. 1 is a schematic illustration of the intoxication pathway for ATx toxin. The PA component of ATx binds to a receptor on the surface of mammalian cells and delivers the enzymic A moieties of the toxin, edema factor (EF) and lethal factor (LF), to the cytosol, as described above.

[0039] FIG. 2A is a picture of SDS-PAGE gels showing the formation of nicked PA mutant proteins and the formation of SDS-resistant oligomers by wild-type, K397Q, and .DELTA.D2L2 PA. FIG. 2B is a picture of a native gel showing the formation of prepores by wild-type, K397A, and D425A PA.

[0040] FIG. 3 is a bar graph showing the amount of ⁸⁶Rb released from ⁸⁶Rb from ⁸⁶Rb loaded cells after incubation with wild-type, K397A, or D425A PA compared to the no PA control.

[0041] FIG. 4A is a bar graph showing the similar level of ³⁵S-LFn (N-terminal 1-255 amino acid PA binding domain of LF) binding by cells that have been incubated with wild-type, K397A, or D425A PA. FIG. 4B is a graph showing the reduction in translocation of ³⁵S-LFn into cells that is mediated by K397A or D425A PA compared to wild-type PA.

[0042] FIG. 5 is a graph showing the percent of ³H-Leu in the TCA insoluble fraction (protein fraction) after incubation of cells with wild-type, K397A, or D425A PA in the LFnDTA toxicity assay. Translocation of LFnDTA, which contains LFn fused to the A-chain of diphtheria toxin, into the cell leads to ribosylation of EF-2, resulting in the inhibition of protein synthesis and a decrease in the amount of ³H-Leu in the protein fraction.

[0043] FIG. 6A is a bar graph showing the similar binding of ³⁵S-LFn to cells incubated with wild-type, .DELTA.D2L2, the double mutant K397D+D425K, or a mixture of wild-type and .DELTA.D2L2 or K397D+D425K PA. FIG. 6B is a bar graph showing the reduction of wild-type PA-mediated translocation of ³⁵S-LFn by .DELTA.D2L2 or K397D+D425K PA.

[0044] FIG. 7 is a graph showing the higher percent of ³H-Leu in the TCA insoluble fraction after incubation of .DELTA.D2L2 or K397D+D425K PA and wild-type PA compared to wild-type PA alone. This result corresponds to a decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay.

[0045] FIG. 8A is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay. Increasing concentrations of

mutant PA proteins relieve the wild-type PA-mediated inhibition of ³H-Leu uptake into the TCA insoluble fraction. FIG. 8B is a graph showing that much higher amounts of PA-SSR relative to wild-type PA are required to relieve the wild-type PA-mediated inhibition of ³H-Leu uptake compared to the amounts required for the mutants listed in FIG. 8A.

[0046] FIG. 9 is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay due to the presence of increasing concentrations of a dominant negative PA mutant. The effect of the dominant negative mutants K397D+D425K (.quadrature.), .DELTA.D2L2 (.box-solid.), F427A (.smallcircle.), D425K (.DELTA.), and K397D (.diamond.) and the control mutant SSSR (.diamond-solid.) are shown in this figure.

[0047] FIG. 10 is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay due to the presence of increasing concentrations of one of the following dominant negative PA mutants: K397D+D425K (.box-solid.), F427A+.DELTA.D2L2 (.quadrature.), K397D+D425K+F427A (.smallcircle.), and K397D+F427A+.DELTA.D2L2 (.tangle-solidup.).

[0048] FIG. 11 is a bar graph showing the inhibition of protein synthesis by a hetero-heptamer formed by mixing wild-type PA with a mutant PA (K397D+D425K, .DELTA.D2L2, F427A, or D425K) and then cleaving the PA molecules with trypsin. Inhibition of protein synthesis by an equivalent amount of a 1:1 mixture of the corresponding mutant and wild-type homo-heptamers was also measured.

[0049] FIG. 12 is a bar graph showing the effect of the dominant negative mutants K397D+D425K, .DELTA.D2L2, F427A, and D425K on the low-pH triggered translocation of ³⁵S LFN across the plasma membrane. The results presented are the mean of three experiments \pm SEM.

[0050] FIG. 13 is the amino acid sequence of wild-type PA protein used for the assays described herein (SEQ ID No.: 21). The PA mutant proteins described herein are based on this wild-type sequence.

[0051] FIG. 14 is the polynucleotide sequence encoding the wild-type PA protein used used for the assays described herein (SEQ ID No.: 22).

[0052] FIG. 15 is an alignment of the amino acid sequence of PA with other binary A-A-B toxins that have ADP ribosyltransferase activity. The amino acid sequences of toxins from *Clostridium difficile* ("cd.DELTA.DPRT"), *C. perfringens* ("cpiota"), *C. spiroforme* ("csiota"), and *C. botulinum* ("cbc2") are listed. The *C. perfringens* and *C. spiroforme* toxins are frequently referred to as iota toxins while the botulinum toxin is referred to as C2. Additionally, the alignment includes the sequence of the toxin produced by *Bacillus cereus* ("VIP1"), which is frequently referred to as VIP for vegetative insecticidal protein.

[0053] FIG. 16 is an alignment of the amino acid sequence of PA with the amino acid sequences of toxins from *Clostridium difficile* ("cdADPRT"), *C. perfringens* ("cpiota"), *C. spiroforme* ("csiota"), and *C. botulinum* ("cbc2"). This alignment shows the complete sequences of the toxins.

DETAILED DESCRIPTION

[0054] We have found a means by which infection by A-B toxin producing bacteria can be halted. Thus, the invention provides a composition for use as an antidote to particular bacterial infections, including anthrax and gangrene. Because the composition is safe and immunogenic, it may also be used as a vaccine.

[0055] The multiple mutants of anthrax PA were constructed, expressed, purified, and assayed to determine whether they have reduced activity compared to wild-type PA. In particular, these mutants were assayed for the ability to bind PA ligands and receptors; to form prepores, SDS-resistant oligomers, and pores; and to translocate ligands across membranes. Based on the x-ray structure of PA, the mutated residues are predicted to project into the lumen of the PA prepore. PA mutants, or fragments thereof, with reduced or no detectable ability to form pores in membranes can be used as vaccines for the induction of protective antibodies to prevent anthrax infection. In addition, these mutants might be more effective than wild-type PA in treating anthrax infection because of their reduced ability to translocate EF and LF secreted by *Bacillus anthracis* in the infected mammal.

[0056] These point mutants and the previously reported deletion mutant lacking residues 302-325 of putative membrane spanning loop 2 of domain 2 (.DELTA.D2L2) (Miller et al., *Biochemistry* 38:10432-10441, 1999) were further characterized to determine whether they could act as dominant negative inhibitors by reducing the pore formation of wild-type PA. This inhibition could result from the binding of ligands or receptors by the mutants so that fewer molecules were available for wild type PA to bind. The mutants could also form oligomers with wild-type PA that have reduced or no detectable ability to form pores and translocate ligands. Dominant negative PA mutants, and fragments thereof, could be used as vaccines to elicit protective antibodies for the prevention or treatment of anthrax infection, as described above. Additionally, mutants or fragments with dominant negative activity could be used as therapeutics to treat anthrax infection by inhibiting the activity of PA secreted by *Bacillus anthracis* in the infected mammal. Because dominant negative mutants can induce the production of protective antibodies and inhibit the activity of PA produced by the infecting bacteria, they can be used as a combination vaccine/therapeutic that is particularly effective in treating individuals suffering from, or at risk of developing, anthrax infection. Besides the need to abrogate toxin action as quickly as possible, it is also important to vaccinate individuals who have been exposed to aerosolized *B. anthracis* spores. This vaccination is essential to guard against delayed contraction of anthrax by germination of spores that can remain in the body for prolonged periods (at least a month).

[0057] In this study, several mutants of PA were identified that lack the ability to form pores in membranes and translocate ligands and, thus, are potential vaccines for the prevention or treatment of anthrax infection (Table 1). Mutants # 1-12 were able to be proteolytically activated, to form the SDS-dissociable PA63 prepore state, and to bind a cellular receptor, EF, and LF. Some of the mutations prevented the conversion of the prepore to an SDS-resistant state (Table 1). These mutants (K397A, K397C, K397D, D425A, D425N, D425K D425E, D425K, K397D+D425K, and K395D+K397D+D425K+D426K) are also defective in pore formation and membrane translocation. The other class of mutants (.DELTA.D2L2 PA, K397Q, and F427A) forms SDS-resistant oligomers but does not undergo membrane insertion and pore formation. These results were unexpected.

1TABLE 1

Activity of Protective Antigen Mutants

Forms SDS-			
Mutant	SEQ ID	resistant	Forms Dominant
#	No.	Mutation	oligomer? channels? negative?
1	1	K397A	No
No	No		

2 2 K397D No No No
 3 3 K397C No No No
 4 4
 K397Q Yes No No
 5 5 D425A No No No
 6 6 D425N No No Not

deter-
 mined
 7 7 D425E No No No
 8 8
 D425K No No Yes
 9 9 F427A Yes No Yes
 10 10 K397D + No No
 Yes
 D425K
 11 11 K395D + No No Yes
 K397D +
 D425K +
 D426K
 12 12 .DELTA.D2L2 Yes No Yes
 13 13
 K397D + Not Not determined Yes
 D425K + determined
 F427A
 14 14 F427A + Not Not determined Yes
 .DELTA.D2L2
 determined
 15 15 K397D + Not Not determined Yes
 F427A +
 determined
 .DELTA.D2L2
 16 16 K397D + Not Not determined
 Yes
 D425K + determined
 F427A +
 .DELTA.D2L2
 17 17 F427D Not Not determined Yes
 determined
 18 18
 F427K Not Not determined Yes
 determined

[0058] These PA mutants were constructed as described in Example 1.

[0059] Several of the mutants (.DELTA.D2L2, K397D+D425K double mutant, K395D+K397D+D425K+D426K quadruple mutant, D425K, F427A, K397D+D425K+F427A triple mutant, F427A+.DELTA.D2L2 double mutant, K397D+F427A+.DELTA.D2L2 triple mutant, K397D+D425K+F427A+.DELTA.D2L2 quadruple mutant, F427D, and F427K) inhibit the wild-type PA-mediated translocation of ligands across membranes. The .DELTA.D2L2 and K397D+D425K PA mutants were shown to form oligomers with wild-type PA that are

unable to translocate ligands. These results were unexpected. The presence of a single molecule of these mutants within a heptameric prepore may be sufficient to block conversion to the pore. This ability to block the pore formation by wild-type PA, coupled with the ability to compete with wild-type PA for the binding of cellular receptors and to remove EF and LF from circulation, makes these mutants particularly attractive for use in the treatment and prevention of anthrax infection.

[0060] Mutation of other residues in PA could also inhibit pore formation or produce dominant negative activity. For example, residues that electrostatically interact with the charged side-chains of Lys397 or Asp425 may also be required for pore formation by PA, and the mutation of one or a combination of these residues may inhibit pore formation and result in dominant negative activity. Additionally, the deletion of smaller portions of the 302-325 D2L2 loop or the deletion of amino acids flanking the loop and part or all of the 302-325 region could produce these results.

[0061] The ability to obtain mutants of PA with no detectable ability to form pores or translocate ligands and mutants that serve as dominant negative inhibitors of wild-type PA suggests that similar mutants could be obtained in other toxins, such as .alpha.-hemolysin from Staphylococcus aureus, aerolysin from Aeromonas hydrophila, .alpha.-toxin from Clostridium septicum, cytotoxin from Pseudomonas aeruginosa, hetero-oligomeric toxins (AB5 toxins), or in the B moieties of tetanus, botulinum, or diphtheria toxins. Additionally, these results underscore the possibility of identifying dominant negative forms of a number of other oligomeric virulence factors, ranging from toxins to adhesins.

[0062] In anthrax toxin and other oligomeric systems in which the assembly process occurs in contact with the extracellular milieu, exogenously added mutant subunits can in principle be incorporated into the final structure, raising the possibility that such subunits could be used therapeutically. Systemic anthrax, although rare as a natural disease, is feared as an agent of biological warfare and terrorism, and dominant negative PA would seem to be a worthy candidate for a therapeutic. Assuming that administered dominant negative PA intermixes freely with wild-type PA produced in the body by B. anthracis, the proteins should co-assemble on cells to form inactive, dead-end complexes, thereby blocking the actions of both LF and EF. Besides preventing overt symptoms, dominant negative mutants may also protect professional phagocytes from destruction, thereby aiding the host in eradicating the infection. No significant side effects have been observed following injection of wild-type PA into humans, and thus a mutant inactive form of the protein should pose no hazard.

[0063] Dominant negative PA may also be useful as a basis for a new vaccine against anthrax. As its name connotes, PA induces protective antibodies against anthrax, and indeed is the major immunogen of the vaccine currently licensed in the United States. The .DELTA.D2L2, K397D+D425K, and F427A mutants described herein exhibit little or no diminution in immunogenicity relative to wild-type PA in Fisher rats. We have also found mutants that are unexpectedly dominant negative, such that administration of a 0.25:1 ratio of mutant to wild-type PA did not result in any detectable symptoms of anthrax infection in a rat model. Purified wild-type PA is under consideration as a replacement for the currently licensed vaccine, and if a dominant negative form of PA proves efficacious therapeutically, it might fulfill this role as well, eliminating the need to develop two almost identical pharmaceuticals.

[0064] The following examples are to illustrate the invention. They are not meant to limit the invention in any way. Unless otherwise noted, the data for the K397A and D425A PA mutants is representative of the data obtained for PA mutants number 1-12 listed in Table 1.

EXAMPLE 1

[0065] General Methods

[0066] Cell Culture, Media and Chemicals

[0067] Chinese hamster ovary-K1 (CHO-K1) cells were obtained from American type culture collection. The cells were grown in HAM's F-12 supplemented with 10% calf serum, 500 units/mL penicillin G, 2 mM L-glutamine and 500 units/mL streptomycin sulfate and maintained at 5% CO₂ in a humidified atmosphere. Cells were seeded into 24- or 96-well microtiter plates (Costar, Cambridge, Mass.) 16-18 hours prior to the experiment. All media for cell culture was obtained from Gibco BRL unless noted otherwise. All chemicals were obtained from Sigma Chemical Co. unless specified.

[0068] Construction and Purification of PA Proteins

[0069] The .DELTA.D2L2 PA mutant, which does not contain amino acids 302-325 of PA, was expressed and purified as described previously (Miller et al., Biochemistry 38:10432-10441, 1999). The point mutations # 1-11 from Table 1 were constructed using the QuickChange method of site directed mutagenesis, following the manufacturer's protocol (Stratagene, La Jolla, Calif.). The plasmid of Miller et al. (supra) encoding wild-type PA was used as the template. The point mutants were cloned into a pET22-b(+) (Novagen) expression vector and transformed into BL21(DE3) (Novagen) for expression. The point mutants were expressed and purified as previously described (Miller, 1999). Briefly, cultures were grown in LB at 37.degree. C. to an A₆₀₀ of 1.0. Expression of the recombinant protein was induced by the addition of .beta.-D-isopropylthiogalactopyranoside to 1 mM. Following induction, the cells were grown for an additional 3 hours at 30.degree. C. and harvested by centrifugation for 10 minutes at 8000.times.g.

[0070] The proteins were released from the periplasm by osmotic shock. The cells were resuspended in 20 mM Tris-HCl, pH 8.0, 30% glucose and 1 mM EDTA and incubated at room temperature for 10 minutes with continuous stirring. The cells were harvested again by centrifugation, resuspended in 5 mM MgSO₄ containing 20 mM Benzamidine. and incubated at 4.degree. C. for 10 minutes with constant stirring. After the cells were again pelleted by centrifugation at 8000.times.g, the periplasmic extract was decanted. Tris-HCl pH 8.0 was added to a final concentration of 20 mM, and the entire sample was loaded onto a Q sepharose HP column. The unbound unbound protein was washed off the column with buffer A (20 mM Tris, pH 8.0). The bound protein was eluted with a 0%-25% buffer B linear gradient (20 mM Tris, pH 8.0, 1 M NaCl). The PA containing fractions were concentrated, and the buffer was exchanged using a pd-10 column (Amersham-Pharmacia) containing buffer A. The PA-containing eluate was loaded onto a Mono-Q column and eluted with a 0-25% buffer B gradient. PA containing fractions were analyzed by SDS-PAGE and stored at -80.degree. C. Proteins concentrations were determined using the Bio-Rad protein assay kit based on the manufacturer's protocol. All liquid chromatography was performed using an AKTA-purifier liquid chromatography system (Amersham-Pharmacia).

[0071] The other PA mutants (# 13-18 from Table 1) were constructed, expressed, and purified similarly.

[0072] Proteolytic Activation of PA

[0073] Trypsin was used to proteolytically cleave PA83 to nicked PA (nPA). PA was diluted to a concentration of 0.5 mg/ml for the prepore-forming assay or 0.2 mg/ml for the other assays. Trypsin was added to a final trypsin to PA ratio of 1:1,000 (w:w), and the mixture was incubated at room temperature for 20 minutes, followed by

by inhibition of the trypsin with a 10 molar excess of soybean trypsin inhibitor.

[0074] Cell Surface Translocation Assay

[0075] A cell surface translocation assay to measure the PA-mediated translocation of radiolabeled LFn (N-terminal 1-255 amino acid PA binding domain of LF) was performed as previously described (Wesche et al., Biochemistry 37:15737, 1998). Briefly, nPA (2.times.10.sup.8 M) was first bound to CHO cells, followed by .sup.35S by .sup.35S LFn which binds to the PA63 on the cell surface. Excess LFn was removed, removed, and the cells were washed and subjected to a pH 5.0 pulse at 37.degree. C. The low pH pulse mimics the acidification of the endosome and results in the PA-mediated translocation of LFn across the plasma membrane and into the cell. The samples were treated with pronase which proteolytically degrades extracellular .sup.35S-LFn, but not .sup.35S-LFn that has been translocated into the cell. The cells were then washed and lysed. To determine the total amount of .sup.35S-LFn that bound to the cells, some of the cells were not treated with pronase. Following lysis, the amount of .sup.35S-LFn in the supernatant was determined using a scintillation counter. The percent translocation was calculated as follows: (DPM protected from pronase)/(DPM bound to cells).times.100=% translocated.

[0076] To determine if mutant PA proteins inhibit the translocation of LFn by wild-type PA, this assay was also performed using equimolar amounts of mutant and wild-type PA that were combined prior to trypsinization and diluted to 2.times.10.sup.-8 M PA (1.times.10 .sup.-8 M of each protein) before being added to cells. When PA at a concentration of 1.times.10 .sup.-8 M was used as a control, the translocation efficiency was only slightly affected by the drop in PA compared to the assay above with 2.times.10 .sup.-8 M wild-type PA, suggesting that any decrease in translocation and binding was not the result of the drop in the concentration of wild-type PA.

[0077] Inhibition of Protein Synthesis

[0078] LFnDTA inhibition of protein synthesis was used as another method to measure PA-mediated translocation of ligands into cells (Milne et al., Mol. Microbiol. 15:66, 1995). For assaying PA mutants # 1-12 in Table 1, CHO-K1 cells were plated at 2.5.times.10.sup.4 cells/well in a 96 well plate 16 hours prior to the addition of PA protein. PA83 (1.times.10.sup.-12 M to 1.times.10.sup.-7 M) was incubated with cells in the presence of 1.times.10.sup.-8 M LFnDTA for 4 hours. The media was then removed and replaced with leucine free HAM's F-12 media supplemented with .sup.3H-Leu at 1 mCi/ml. After a one hour incubation, the cells were washed with ice cold PBS followed by ice-cold trichloro acetic acid (10%) to precipitate proteins. The quantity of .sup.3H-leu incorporated into the TCA insoluble material was determined using a scintillation counter and was used as a measure of the amount of newly synthesized protein.

[0079] Mutant PA proteins were also tested in this assay to see if they relieved the the wild-type PA-mediated inhibition of .sup.3H-Leu uptake. Wild-type PA was added to CHO cells at a concentration of 1.times.10.sup.-9 M with 1.times.10.sup.-8 M LFnDTA. Increasing amounts of one of the mutants were also added. The cells were incubated with the toxin for 4 hours and the samples were processed as described above.

[0080] The PA mutants listed in FIG. 9 were tested similarly. CHO-K1 cells (2.5.times.10.sup.4 cells/well) in a 96-well plate were incubated for 18 hours at 37.degree. C. with wild-type PA (100 pM) in the presence of LFN-DTA (100 pM) and various amounts of individual PA mutants (K397D+D425K, .DELTA.D2L2, F427A, D425K, K397D, or SSSR). The medium was then removed and replaced with leucine-free HAM F-12

12 supplemented ^{3}H -Leu at 1 $\mu\text{Ci/ml}$. After incubation for one hour at 37.degree. C., the cells were washed with ice-cold PBS followed by ice-cold 10% trichloroacetic acid (TCA). The quantity of ^{3}H -Leu incorporated into the TCA-precipitable material was measured and is expressed as percent of that incorporated in the absence of PA. At the concentrations of wild-type PA and LFnDTA chosen, protein synthesis was inhibited by about 90% in the absence of mutant PA (dotted line). The mean of three experiments \pm SEM is reported. Similar results were seen when the initial incubation was four hours, instead of 18 hours. The K397D+D425K+F427A, F427A+.DELTA.D2L2, and K397D+F427A+.DELTA.D2L2 PA mutants listed in FIG. 10 were tested similarly.

[0081] The PA-mediated inhibition of protein synthesis by hetero-heptamers of wild-type and mutant PA was compared to that of mixtures of the corresponding homo-heptamers. Homo-heptamers of wild-type PA63 and K397D+D425K, .DELTA.D2L2, F427A, K397D, and D425K mutants, were prepared as described above. Putative hetero-heptamers were prepared by mixing each mutant PA with wild-type PA in a 1:1 ratio before trypsinization and column chromatography (FIG. 11). Wild-type PA (1 nM), hetero-heptamer (H) (final concentration 2 nM), or an equimolar mixture (M) (1 nM each) of the corresponding mutant homo-heptamer and wild-type-heptamer, was incubated with CHO-K1 cells in the presence of LFnDTA (100 pM) for 18 hours, and inhibition of protein synthesis was measured as described above for FIG. 9. Heptamer concentrations are expressed in terms of monomeric PA63 sub units. Protein synthesis is expressed as the percent of a control without PA. The mean of three experiments \pm SEM is reported. Similar results were seen after a four hour incubation.

[0082] Prepore and SDS-resistant Oligomer Formation

[0083] The formation of prepores and SDS-resistant oligomers was measured by incubating nPA with an equimolar amount of LFn for 30 minutes at room temperature. To determine whether prepores had formed, the samples were subjected to electrophoresis in a 4-12% native gradient gel (FMC) using 50 mM CHES, pH 9.0, 2 mg/ml CHAPS as the running buffer. To determine whether low pH induced the formation of SDS-resistant heptamers, 100 mM sodium acetate, pH 4.5 was added until the pH of the solution reached 5.0, and then the sample was incubated at room temperature for 30 minutes. The sample was then dissolved in SDS-PAGE sample buffer and run on a 4-12% SDS-PAGE gradient gel. Proteins in the gels were visualized with coomassie brilliant blue.

[0084] Rubidium Release

[0085] CHO-K1 cells were plated at a density of 2.times.10.sup.5 cells/well and incubated at 37.degree. C. for 24 hours. The media was then aspirated and replaced with media containing 1 $\mu\text{Ci/ml}$ $^{86}\text{RbCl}$ and incubated for 16 hours. The cells were chilled on ice for 20 minutes, and the media was removed. The cells were washed, and nPA (2.times.10.sup.-8 M) in HEPES buffered media was added. The cells were incubated with nPA for 2 hours on ice, followed by the addition of ice cold pH 5.0 buffer. After 30 minutes, samples from the supernatant were collected and counted in a scintillation counter to determine the amount of released ^{86}Rb .

[0086] This standard assay may also be used to determine the effect of other pore-forming toxins on the amount of released ^{86}Rb . Thus, other mutant toxins of the the present invention may be tested in this assay to determine whether they have a reduced ability to form transmembrane pores.

EXAMPLE 2

[0087] Failure of Most Mutants to Form SDS-resistant Oligomers

[0088] All PA mutants # 1-12 in Table 1 and wild type PA proteins were proteolytically nicked with trypsin as described above, forming nicked PA (nPA) proteins that migrated as lower molecular species when analyzed by SDS-PAGE (FIG. 2A). Formation of SDS-dissociable prepores by PA mutants # 1-12 in Table 1 was detected by the decreased mobility in native gels of heptameric PA63 complexed with LFn compared to monomeric nPA (FIG. 2B). The formation of prepores by the K397A and D425A PA mutants was further supported by the elution of the prepores from a MonoQ column at a higher salt concentration than that which elutes monomeric PA. The nPA mutants were also analyzed for the formation of SDS-resistant oligomers. As a positive control, wild-type PA was treated with LFn. The low pH pulse converted wild-type PA into SDS-resistant oligomers, which migrated as high molecular weight complexes when analyzed by SDS-PAGE. .DELTA.D2L2 (PA lacking residues 302-325) and K397Q (FIG. 2B). Wild-type, K397Q, F427A, and .DELTA.D2L2 PA formed SDS-resistant oligomers when treated with low pH (FIG. 2A and Table 1).

EXAMPLE 3

[0089] Failure of PA Mutants to Form Pores in Membranes

[0090] The failure of most of the PA mutants to form SDS-resistant oligomers suggested that pore formation in cell membranes would also be inhibited. Pore formation was assayed by binding nPA proteins to cells loaded with the radioactive potassium analogue, ⁸⁶Rb, pulsing with low pH, and measuring the release of ⁸⁶Rb into the surrounding media, as described in Example 1. Wild-type nPA induced the release of ⁸⁶Rb due to the insertion of nPA into the membrane forming ion permeable pores. In contrast, none of the mutants # 1-12 in Table 1 induced ⁸⁶Rb release (FIG. 3 and Table 1). Thus, the inability of most PA mutants to form SDS-resistant oligomers (Example 2) correlates with an inability of these mutants to form pores in cell membranes.

EXAMPLE 4

[0091] Failure of PA Mutants to Translocate LFn Across Membranes

[0092] Pore formation is a requisite step in the PA dependent translocation of ligands (i.e., LF, EF or LFn) across membranes. A cell surface translocation assay was used to directly measure the translocation of PA ligands into the cytoplasm of the cell (Example 1). None of the PA mutants # 1-12 in Table 1 had a significantly decreased ability to bind LFn (FIG. 4A); however, all of the assayed mutants had a significantly reduced ability to translocate LFn in this assay (FIGS. 4B and 12). The SSSR control mutant caused little inhibition under these conditions. These data suggest that the mutants retain structural integrity and the ability to bind to the cellular receptor and LFn but are not able to form pores or translocate ligands across membranes.

EXAMPLE 5

[0093] Failure of PA Mutants to Translocate LFnDTA Across Membranes

[0094] Another method used to measure translocation of PA ligands across membranes is the LFnDTA toxicity assay (Example 1). In this assay, CHO cells are treated with PA and a ligand containing LFn fused to the A-chain of diphtheria toxin DTA (LFnDTA). The translocated A-chain of diphtheria toxin ADP ribosylates the cytoplasmic protein EF-2, resulting in the inhibition of protein synthesis and the induction of cell death. This assay is a measure of translocation of a ligand from an endosomal compartment as opposed to a cell surface, as measured in Example 4. After incubation with LFnDTA and wild-type or mutant PA, cells were washed and incubated in leucine-free media supplemented with ³H-leucine. If protein

synthesis is not inhibited, ³H-leucine will be incorporated into newly synthesized proteins. If protein synthesis is inhibited by LFnDTA, little ³H will be incorporated. All of the mutants tested did not significantly inhibit protein synthesis in this assay (FIG. 5). This result further supports the hypothesis that the lack of significant pore formation by PA mutants results in decreased membrane translocation of PA ligands by these mutants.

EXAMPLE 6

[0095] Inhibition of Wild-type PA Pore Formation by PA Mutants

[0096] Since all of the PA mutants # 1-12 in Table 1 were defective in pore formation, they were tested to determine whether they could form inactive hetero-oligomers with wild-type PA thus inhibiting PA-mediated translocation of ligands across membranes. DELTA.D2L2, K397D+D425K, and K395D+K397D+D425K+D426K PA inhibited wild-type PA in this manner. When mixed with an equimolar amount of wild-type PA, each of these three mutants markedly inhibited translocation of ³⁵S-LFn into the cells in the cell surface translocation assay (FIG. 6). ³⁵S-LFn binding to cells was not inhibited (FIG. 6).

EXAMPLE 7

[0097] Inhibition of Wild-type PA Pore Formation by PA Mutants

[0098] The effect of these mutant proteins on PA mediated LFnDTA toxicity was also measured. When the DELTA.D2L2, K397D+D425K double mutant, or K395D+K397D+D425K+D426K quadruple mutant PA was mixed with an equimolar amount of wild-type PA in the LFnDTA assay, there was an approximately 2-log decrease in the wild-type PA-mediated inhibition of ³H-Leu (FIG. 7). Thus, the mutants inhibited PA-mediated translocation by 99%. The activity retained in the presence of the mutant proteins is probably the result of heptamers containing 7 wild-type PA molecules and 0 mutant PA molecules (WT.sub.7Mut.sub.0). Using Pascal's triangle, 1% of the heptamers formed from the equimolar mixture of wild-type and mutant PA are expected to be 100% wild-type (WT.sub.7Mut.sub.0) (Table 2). This calculated result agrees with the 1% experimentally measured residual activity present in the mixture. Inhibition studies in which various ratios of wild-type to DELTA.D2L2 or K397D+D425K mutant PA were tested in the LFnDTA assay indicate that the only active species in the mix is probably WT.sub.7Mut.sub.0. Thus, the majority of heptamers containing one molecule of DELTA.D2L2 or K397D+D425K PA are inactive (Table 2), further supporting the dominant negative nature of these inhibitors.

2TABLE 2

Predicted and Measured Compositions of PA
Oligomers Formed from
Various Ratios of Mutant to Wild-type PA

Predicted % of the Activity Retained
total heptamer
population DELTA.D2L2 K397D +
Mutant:Wt (mole:mole)
WT.sub.7Mut.sub.0 WT.sub.6Mut.sub.1 WT.sub.5Mut.sub.2 Mix D425A Mix

1:1 0.78% 6% 22% 0.7% .+-. .2 0.9% .+-. .06
0.75:1 2

```

10.4 23.5% 3.8% .+- .2 1.2% .+- .2
0.5:1 5.8 25.8 56.8 13.5%
.+- .5 5.8% .+- 3.6
0.25:1 21 57 85 14.3% .+- .2 10% .+- .2

```

The predicted values represent the percent of the total heptamers that are expected to have at least the indicated number of wild-type molecules in the mixtures containing varying ratios of mutant and wild-type PA.

The WT.sub.7Mut.sub.0 column represents the percent of the total heptamers that are expected to contain seven wild-type PA molecules. The WT.sub.6Mut.sub.1 # column represents the percent of the total heptamers that are expected to contain at least six wild-type PA molecules # (i.e., the heptamers that either contain six wild-type PA molecules and one mutant PA molecule or contain seven wild-type PA molecules and zero mutant PA molecules. Similarly, the WT.sub.5Mut.sub.2 column represents the percent of the total heptamers that are expected to contain at least five wild-type PA molecules. These values were calculated using Pascal's triangle. The values listed under "Activity Retained" # are the actual experimental values seen in these mixtures.

[0099] A titration of mutant with wild-type PA in the LFnDTA assay was performed to further characterize the inhibition of wild-type PA. Increasing amounts of one of the mutants was added to incubations of cells with wild-type PA and LFnDTA (FIG. 8A). The mutant PA-SSSR, which has the furin recognition site mutated from .sup.164RKKR.sup.167 to .sup.164SSSR.sup.167, was included as a control. Since this mutant cannot be nicked by furin or other furin-like proteases and thus can not form pores, the mutant can only inhibit PA by competing for the receptor. Both .DELTA.D2L2 and K397D+D425K greatly inhibited PA mediated translocation. Most importantly these mutants do not inhibit solely by competing for the receptor since far less protein is required by these mutants to see 50% inhibition than is required by PA-SSSR (FIG. 7B). The single mutant constituents of K397D+D425K do not inhibit as well as the double mutant but inhibit better than PA-SSSR. Taken together these data suggest that .DELTA.D2L2, K397D+D425K, and K395D+K397D+D425K+D426K PA are dominant negative inhibitors of wild-type PA.

[0100] The dominant negative inhibitory activity of the F427A, D425K, K397D+D425K+F427A, F427A+.DELTA.D2L2, K397D+F427A+.DELTA.D2L2 PA mutants was also measured. For this assay, increasing amounts of the mutant forms of PA were mixed with a constant amount of wild-type PA as described above. The most potent member of this group, the K397D+D425K+F427A triple mutant, almost completely blocked toxin action at a 1:1 ratio of mutant:wild-type PA. The D2L2, K397D+D425K, F427A, F427A+.DELTA.D2L2, and K397D+F427A+.DELTA.D2L2 PA mutants also had inhibitory activity. The K397D+D425K+F427A+.DELTA.D2L2, F427D, and F427K PA mutants also exhibited dominant negative activity in the LFnDTA toxicity assay. In contrast, another translocation-deficient mutant, K397D, caused virtually no inhibition at a 1:1 ratio, showing that not all mutants of this type are strongly inhibitory (FIG. 9). The SSSR control mutant caused no detectable inhibition of toxin action, even in 10-fold excess over wild-type PA, implying that competition for receptors did not contribute significantly to the inhibitory activities of the other mutants.

[0101] The hypothesis that inhibition by the dominant negative mutants depends upon the ability of their PA63 moieties to form hybrid complexes with wild-type PA63 was tested using purified homo- and hetero-heptamers. PA in solution can be cleaved at the furin site by mild trypsinization, and the resulting fragments can be separated by chromatography of the trypsin-nicked molecule on an anion-exchange column (Miller (Miller et al, Biochemistry 38, 10432, 1999). Purified PA63 isolated by this method is heptameric, indicating that the oligomerization equilibrium is greatly in favor of this form, and may be structurally similar or identical to the prepore. Purified homo-heptamers were prepared from wild-type PA and each of the K397D+D425K, .DELTA.D2L2, F427A, D425K, and K397D translocation deficient PA mutants. Putative hetero-heptamers were prepared by mixing each mutant PA 1:1 with wild-type PA, followed by trypsinization of the mixture and chromatography of the products on an anion-exchange column.

[0102] The LFnDTA-dependent inhibition of protein synthesis by each hetero-heptamer and by an equivalent amount of a 1:1 mixture of the corresponding mutant and wild-type homo-heptamers was measured. Hetero-heptamers containing the K397D+D425K, .DELTA.D2L2, F427A and D425K mutants did not mediate the action of LFnDTA, whereas the corresponding mixtures of homo-heptamers were highly active (FIG. 11). In contrast, the putative hetero-heptamer formed by mixing K397D with wild-type PA was as active as the mixture of homo-K397D PA and homo-wild-type PA. These results are consistent with the properties of these mutants in the experiment of FIG. 9 and support the notion that PA63 from the dominant negative mutants inactivates the wild-type protein by co-oligomerizing with it. The absence of inhibitory activity of K397D in the hetero-heptamer preparation may reflect a defect either in ability to co-oligomerize with the wild-type protein or in ability to inhibit its activity within a heptamer. The finding that mutant homo-heptamers did not inhibit the activity of the wild-type indicates that little competition for receptors and little little or no subunit exchange among heptamers occurred under the conditions of the experiment.

[0103] As described above, the fact that the K397D+D425K double mutant almost completely blocked activity in these LFnDTA toxicity assays suggests both that a single molecule of the mutant inactivates a heptamer and that oligomerization is stochastic. The .DELTA.D2L2, D425K, and F427A mutants appear to be slightly less inhibitory, implying that more than one molecule of these mutants per heptamer may be required for inactivation and/or that their co-oligomerization with wild-type PA may not be purely stochastic. Other factors, such as the order of addition of B moieties to a growing heptamer complex (e.g., the B moiety that is added first or last) may also effect inactivation. It is not intended that the invention be limited by any proposed mechanism for inhibition set forth in the specification.

EXAMPLE 8

[0104] Formation of SDS-resistant Oligomers Containing Mutant and Wild-type PA

[0105] To examine the interaction of .DELTA.D2L2 and K397D+D425K mutants with wild-type PA, an equimolar ratio of mutant to wild-type PA was mixed, nicked with trypsin, and analyzed by SDS-PAGE for SDS-resistant oligomer formation. When either mutant was mixed with wild-type PA, a new species of SDS-resistant PA was formed. In contrast to wild-type PA alone which produces a diffuse high molecular weight smear in the gel, the mixture of mutant and wild-type PA results in the formation of a sharp high molecular weight band. This sharp band also differs from what is seen for either of the mutants alone: K397D+D425K alone does not form an SDS-resistant oligomer, and .DELTA.D2L2 PA alone forms an oligomer which migrates farther in the gel than the band formed when wild-type PA is also present. Although the exact composition or nature of this band has not been determined, this band further suggests that the mutants interact with wild-type PA in SDS-resistant oligomers resulting in a change in the mobility of the oligomer in the gel.

EXAMPLE 9

[0106] Toxin Inhibition in vivo

[0107] The properties displayed by the dominant negative mutants in vitro imply that that they should inhibit toxin action in vivo. To test this hypothesis, activities of three of these mutants (K397D+D425K, .DELTA.D2L2, and F427A) were measured in a classical in vivo model for anthrax toxin action, the Fisher 344 rat (Ivins et al., Appl. Environ. Microbiol. 55:2098, 1989). Male rats (250-300 g) injected intravenously with a mixture of 8 .mu.g LF and 40 .mu.g PA (approximately 10 times the minimal lethal dose) become moribund after about 90 minutes (Table 3). When wild-type PA was replaced with any of the dominant negatives mutants, the animals showed no symptoms of intoxication during the two week time period before the animals were sacrificed. When a dominant negative PA was added to the wild-type PA/LF mixture before injection, either at a 1:1 ratio relative to wild-type PA (40 .mu.g dominant negative PA) or at a 0.25:1 ratio (10 .mu.g dominant negative PA), the injected animals also survived without symptoms. The SSSR mutant had little effect on the activity of the toxin. These results are consistent with our in vitro results and demonstrate that the dominant negative mutants can ablate anthrax toxin action in vivo, even at a sub-stoichiometric (0.25:1) ratio to wild-type PA.

3TABLE 3

Inhibition of wild-type PA by PA mutants
in vivo

Quantity of protein (.mu.g)

K397D +

WT

.DELTA.D2L2 D425K F427A SSR TTM

40 -- -- -- 90 .+-. 11

min

-- 40 -- -- -- Survived

-- -- 40 -- -- Survived

-- -- -- 40 -- Survived

40 40 -- -- -- Survived

40 -- 40 --

-- Survived

40 -- -- 40 -- Survived

40 -- -- -- 40 100 .+-. 3

min

40 10 -- -- -- Survived

40 10 -- -- Survived

40 -- -- 10 -- Survived

[0108] The ability of the K397D+D425K+F427A triple mutant ("Triple") to inhibit the activity of wild-type PA in vivo was compared to that of the K397D+D425K double mutant ("Double") (Table 4). This experiment was performed as described above using rats injected with a mixture of 40 .mu.g wild-type PA, 10 .mu.g LF, and either PBS or a dominant negative PA mutant.

4TABLE 4

Inhibition of wild-type PA by PA mutants
in vivo
amount of
Animals mutant PA TTM

PBS 2 -- .about.100 minutes
Double 2 40 .mu.g Survived

Triple 2 40 .mu.g Survived
Double 4 4 .mu.g Survived

Triple 4 4 .mu.g Survived

[0109]. The anti-PA and the neutralizing antibody titer generated by vaccination of rats with K397D+D425K, .DELTA.D2L2, or F427A PA was also measured. For this determination, groups of six animals were vaccinated three times each at 0, 3, and 6 weeks with 50 .mu.g of protein in 200 .mu.l of Ribi Tri-Mix adjuvant (Sigma) by intramuscular injection into the hind-quarters. Two days prior to the first injection and 14 days following each injection, blood was drawn from each animal and the serum was collected. Sixteen days following the final injection the rats were challenged with a lethal dose of LF (30 .mu.g PA+6 .mu.g LF) by IV injection as described in Table 5. The mean anti-PA antibody titers in the serum were determined in a standard ELISA assay against PA. The titers are reported as the reciprocal of the geometric mean of the dilution at which the reactivity of the serum ends. Neutralizing antibodies were titered in an LFnDTA assay at 1.times.10.sup.-10 M PA and 1.times.10.sup.-10 M LFnDTA. Antibody dilutions were incubated with PA at 37.degree. C. for one hour prior to starting the assay. Protein synthesis inhibition was measured using the LFnDTA toxicity assay as described above. The neutralizing titers are represented as the reciprocal of the geometric mean dilution required to inhibit PA activity by 50%. As illustrated in Table 5, the K397D+D425K, .DELTA.D2L2, and F427A PA mutants exhibited little or no diminution in immunogenicity relative to wild-type PA in Fisher rats. The neutralizing and anti-PA antibody titers, after three injections were similar, regardless of immunogen employed, and all vaccinated animals survived challenge with a lethal dose of wild-type PA plus LF administered 16 days after the last injection.

5TABLE 5

Anti-PA and the neutralizing antibody
titer generated by vaccination of
rats with PA mutants

Animals Anti-PA Titer Neutralizing Titer TTM

PBS 6 <10
<10 74.2 .+-. 1.5
WT 5 43,300 2,490 Survived
.DELTA.D2L2

6 47,500 3,350 Survived
K397D + 6 65,500 2,260 Survived

D425K
F427A 6 132,000 6,090 Survived

EXAMPLE b 10

[0110] Antibodies to PA

[0111] Antibodies to a PA protein may be used as therapeutics and/or diagnostics. Antibodies may be produced using standard methods by immunologically challenging a B-cell-containing biological system, e.g., an animal such as a mouse or rabbit, with a PA protein or a fragment thereof to stimulate production of an anti-PA antibody by the B-cells, followed by isolation of the antibody from the biological system. For the generation of monoclonal antibodies, the spleen may be harvested from the animal with the highest ELISA-determined immune response to the PA protein, and the B-cells fused to NS-1 myeloma cells to generate hybridomas. Hybridomas that secrete antibodies which bind PA may be selected using a standard ELISA assay or by western blotting. Monoclonal cell lines producing a high antibody titer and specifically recognizing a PA protein are saved.

[0112] The cell lines may also be screened to identify lines that produce antibodies which bind naturally-occurring PA with greater affinity than a mutant PA protein. These antibodies may be generated by administering to animals fragments of naturally-occurring PA that contain residues such as K397, D425, D426, or F427. The resulting antibodies may then be screened to determine which antibodies bind naturally-occurring PA but do not bind a mutant PA protein in which one or more of residues K397, D425, D426, or F427 is mutated or deleted. For example, the antibodies may be applied to a column containing an immobilized mutant PA protein, and the antibodies that do not bind the mutant PA protein may be selected. Antibodies may also be generated that are reactive with residues in the D2L2 loop; these antibodies may be produced by administering a fragment of PA containing the D2L2 loop to an animal, as described above. Antibodies that are reactive with residues in the D2L2 loop of naturally-occurring PA may also be screened to select the antibodies that do not bind a mutant PA protein in which one or more residues in the D2L2 loop are deleted. Alternatively, antibodies may be generated that bind a mutant PA with greater affinity than a naturally-occurring PA molecule by administering a fragment of a mutant PA to an animal as described above and selecting the antibodies with greater affinity for the mutant PA form. These antibodies may bind a residue in a mutant PA that is not present in a naturally-occurring PA.

[0113] Anti-PA antibodies may be used to measure PA protein in a biological sample such as serum, by contacting the sample with the antibody and then measuring immune complexes as a measure of the PA protein in the sample. Thus, these antibodies may be used in kits to determine whether a subject has been exposed to anthrax toxin.

[0114] Antibodies to PA can also be used as therapeutics for the treatment or prevention of anthrax infection. If a anti-PA antibody that binds wild-type PA but does not bind a dominant negative PA mutant is administered to a subject for passive immunization against anthrax infection, a dominant negative PA mutant may also be administered to the same subject as a therapeutic to inhibit the activity

of wild-type PA. Because the administered anti-PA antibody does not react with the therapeutic dominant negative PA mutant, the anti-PA antibody should not reduce the ability of the dominant negative PA mutant to inhibit wild-type PA. Additionally, an anti-PA antibody that does not react with a therapeutic dominant negative PA mutant may be used to determine the amount of wild-type PA present in a sample from a subject who has been treated with the dominant negative PA mutant.

[0115] Similar antibodies may be generated for other mutant B moieties of the present invention.

EXAMPLE 11

[0116] Administration of PA Proteins and Fragments

[0117] It is not intended that the administration of the PA proteins or fragments of the invention be limited to a particular mode of administration, dosage, or frequency of dosing; the present mode contemplates all modes of administration, including oral, intramuscular, intravenous, subcutaneous, by inhalation, or any other route sufficient to provide a dose adequate to prevent or treat an anthrax infection. One or more of the mutant PA proteins or fragments may be administered to a mammal in a single dose or multiple doses. When multiple doses are administered, the doses can be separated from one another by, for example, one week to one month. It is to be understood that for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.

[0118] The pharmaceutical compositions containing one or more PA proteins or fragments of the invention can be prepared as described previously in Remington's Pharmaceutical Sciences by E. W. Martin. Pharmaceutical stabilizing compounds, delivery vehicles, carrier vehicles, or adjuvants may be used. For example, human serum albumin or other human or animal proteins can be used. Phospholipid vesicles or liposomal suspensions are possible pharmaceutically acceptable carriers or delivery vehicles. Adjuvants that can be used in the invention include aluminum compounds, such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate. These compositions can be prepared according to methods known to those skilled in the art.

[0119] Other mutant B moieties or fragments of the invention may be administered similarly.

EXAMPLE 12

[0120] Other Pore-forming Mutants

[0121] The crystal structure of PA identified four domains of PA (Petosa et al., Nature 385(6619): 833-838, 1997). Domain 2 (residues 259-487) contains a large flexible loop that may undergo a major conformational change during conversion from the prepore to the pore. Mutation, deletion, or insertion of one or more amino acids in this region may result in inhibition of the pore-forming ability of the protein in vivo and/or result in the ability of the PA mutant to inhibit the pore-forming ability of naturally-occurring PA. For example, residues in domain 2 of PA that are identical to the corresponding residues in one or more other pore-forming toxins (such as toxins from *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis*; FIGS. 15 and 16) may be mutated. These residues may be mutated or deleted in PA to generate dominant negative PA mutants. The following residues of domain 2 in PA are invariant among the binary A-B toxins listed in FIGS. 15 and 16: A259, P260, V262, V264, M266,

E267, S272 E275 T298, N353, N361, N363 R365, Y366, N368, G370, T371, Y375, V377, P389, T380, T381, V384, T393, I394, P407, Y411, P412, A420, D425, F427, I432, N435, Q438, L450, T452, Q454, G457, G474, W477, and I484. These residues may be mutated to to any other amino acid. For example, the residues may be changed to an amino acid with a smaller side chain such as glycine or alanine, or the residues may be changed changed to an amino acid with a larger or branched side chain such as tryptophan, leucine, or methionine. Additionally, charged residues may be changed to residues with a neutral side chain or residues with a side chain of the opposite charge. Other examples of residues that may be used to replace a naturally-occurring residue residue are listed in Table 1.

[0122] In addition to anthrax toxin, the present invention is relevant to other pore-forming toxins. These toxins may also be mutated to generate toxins with reduced or negligible ability to oligomerize, to form transmembrane channels, or to translocate a ligand. Additionally, dominant negative mutants of other pore-forming mutants may be generated. For example, mutations that correspond to the PA mutations described herein may be made in other toxins that are homologous to PA (such as toxins from *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis*) (FIGS. 15 and 16 and Table 6). Residues in other toxins that correspond to residues in domain 2 of PA may be mutated as described above. Additionally, at least 1, 3, 5, 8, 10, 15, 20, or 24 of the amino acids in the region that corresponds to the D2L2 loop of PA may be deleted in other pore-forming toxins. Also, one or more point mutations may be made at residues that correspond to the mutated PA residues described herein.

[0123] Any of these mutant forms of pore-forming toxins may be administered to a mammal for the treatment or prevention of infection by the pathogens (e.g., bacteria) that produce the corresponding toxin.

6TABLE 6

Mutations in other pore-forming toxins that correspond to the mutations in anthrax PA which are described herein.

The residues in the other pore-forming toxins that correspond to the residues that were mutated in PA may also be mutated to any other amino acid.

C. C. C.
anthrax C.
difficile perfringens spiroforme botulinum B. cereus
 PA toxin
 toxin toxin toxin toxin

K397A Q425A Q424A Q428A Q398A
 K879A
 K397D Q425D Q424D Q428D Q398D K879D
 K397C Q425C Q424C
 Q428C Q398C K879C
 K397Q Q425Q Q424Q Q428Q Q398Q K879Q
 D425A
 D453A D452A D456A D426A D907A
 D425N D453N D452N D456N D426N D907N

 D425E D453E D452E D456E D426E D907E
 D425K D453K D452K D456K

D426K D907K
 F427A F455A F454A F458A F428A F909A
 K397D +
 Q425D + Q424D + Q428D + Q398D + K879D +
 D425K D453K D452K D456K
 D426K D907K
 K395D + K423D + K422D + K426D + K396D + T877D

 K397D + Q425D + Q424D + Q428D + Q398D + K879D +
 D425K + D453K +
 D452K + D456K + D426K + D907K +
 D426K Q454K Q453K Q457K Q427K
 D908K
 .DELTA.D2L2 .DELTA.340-358 .DELTA.339-357 .DELTA.343-361
 .DELTA.307-331 .DELTA.797-816
 K397D + Q425D + Q424D + Q428D +
 Q398D + K879D +
 D425K + D453K + D452K + D456K + D426K + D907K +

 F427A F455A F454A F458A F428A F909A
 F427A + F455A + F454A +
 F458A + F428A + F909A +
 .DELTA.D2L2 .DELTA.340-358 .DELTA.339-357
 .DELTA.343-361 .DELTA.307-331 .DELTA.797-816
 K397D + Q425D + Q424D
 + Q428D + Q398D + K879D +
 F427A + F455A + F454A + F458A + F428A +
 F909A+
 .DELTA.D2L2 .DELTA.340-358 .DELTA.339-357 .DELTA.343-361
 .DELTA.307-331 .DELTA.797-816
 K397D + Q425D + Q424D + Q428D +
 Q398D + K879D +
 D425K + D453K + D452K + D456K + D426K + D907K +

 F427A + F455A + F454A + F458A + F428A + F909A +
 .DELTA.D2L2
 .DELTA.340-358 .DELTA.339-357 .DELTA.343-361 .DELTA.307-331
 .DELTA.797-816
 F427D F455D F454D F458D F428D F909D
 F427K
 F455K F454K F458K F428K F909K

[0124] Alternatively, random mutagenesis may be performed on nucleic acids encoding pore-forming mutants (such as cholesterol dependent cytolysins or hexameric or heptameric toxins related to the Staphylococcal .alpha.-toxin) using standard molecular biology methods. The encoded mutant toxins may be expressed and optionally optionally purified using standard methods. The rubidium release assay described herein may be used to identify mutant toxins with a reduced ability to form a trans membrane channel. Additionally, animal models may be used to identify dominant negative toxin mutants that reduce the toxicity of the corresponding wild-type toxin when both the mutant and wild-type toxins are administered to the animal.

[0125] Other Embodiments

[0126] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

[0127] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

[0128] Other embodiments are within the claims.

CLAIMS:

1. A B moiety of a pore-forming binary A-B toxin, wherein said B moiety comprises a mutation that inhibits its pore-forming ability.
2. The B moiety of claim 1, wherein said B moiety is anthrax protective antigen.
3. The B moiety of claim 1, wherein said B moiety lacks pore-forming ability.
4. The B moiety of claim 1, having an amino acid sequence that is at least 80% identical to SEQ ID No.: 21 and that has an alteration selected from the group consisting of: a) K397A; b) K397D; c) K397C; d) K397Q; e) D425A; f) D425N; g) D425E; h) D425K; i) F427A; j) K397+D425K double mutation; k) K395D+K397D+D425K+D426K quadruple mutation; l) K397D+D425K+F427A triple mutation; m) F427A+.DELTA.D2L2 double mutation; n) K397D+F427A+.DELTA.D2L2 triple mutation; o) K397D+D425K+F427A+.DELTA.D- 2L2 quadruple mutation; p) F427D; q) F427K; and (r) .DELTA.D2L2.
5. The B moiety of claim 1, wherein said mutation is not the deletion of amino acids 302-325 of anthrax protective antigen (SEQ ID NO. 12).
6. A vaccine composition comprising a B moiety of a pore-forming binary A-B toxin or a fragment thereof in a pharmaceutically acceptable carrier, wherein said B moiety comprises a mutation that inhibits its pore-forming ability.
7. The vaccine composition of claim 6, wherein said B moiety is anthrax protective antigen.
8. The vaccine composition of claim 6, wherein said B moiety is inactivated by chemical or physical means.
9. A method of preventing bacterial infection in a mammal, said method comprising administering to said mammal a vaccine comprising a B moiety of a pore-forming binary A-B toxin or a fragment thereof in a pharmaceutically acceptable carrier, wherein said B moiety comprises a mutation that inhibits its pore-forming ability.
10. A method of treating bacterial infection in a mammal, said method comprising administering to said mammal a vaccine comprising a B moiety of a pore-forming binary A-B toxin or a fragment thereof in a pharmaceutically acceptable carrier, wherein said B moiety comprises a mutation that inhibits its pore-forming ability.

11. The method of claim 9 or 10, wherein said vaccine is administered with an adjuvant.

12. A mutant B moiety of a pore-forming binary A-B toxin, wherein said mutant B moiety comprises a mutation that inhibits its pore-forming ability, and wherein said said mutant B moiety inhibits the pore-forming ability of a naturally-occurring B moiety of said toxin.

13. The mutant B moiety of claim 12, wherein said mutant B moiety is anthrax protective antigen.

14. The mutant B moiety of claim 13, having the ability to bind lethal factor or edema factor.

15. The mutant B moiety of claim 12, having the ability to compete with said naturally-occurring B moiety for binding to a receptor on the surface of a mammalian cell.

16. The mutant B moiety of claim 12, having the ability to bind said naturally-occurring B moiety.

17. The mutant B moiety of claim 12, having the ability to oligomerize with said naturally-occurring B moiety to form a complex that has reduced ability to form a pore.

18. The mutant B moiety of claim 17, wherein said complex lacks the ability to form a pore.

19. The mutant B moiety of claim 12, having an amino acid sequence that is at least 80% identical to SEQ ID No.: 21 and that has an alteration selected from the group consisting of: a) K397D+D425K double mutation; b) .DELTA.D2L2; c) K395D+K:397D+D425K+D426K quadruple mutation; d) D425K; e) F427A; f) K397D+D425K+F427A triple mutation; g) F427A+.DELTA.D2L2 double mutation; h) K397D+F427A+.DELTA.D2L2 triple mutation; i) K397D+D425K+F427A+.DELTA.D2L2 quadruple mutation; h) F427D; and i) F427K.

20. The mutant B moiety of claim 12, comprising a deletion of at least 5 amino acids of the D2L2 loop.

21. A method of preventing bacterial infection in a mammal, said method comprising administering to said mammal a mutant B moiety of a pore-forming binary A-B toxin or a fragment thereof, wherein said mutant B moiety comprises a mutation that inhibits its pore-forming ability, and wherein said mutant B moiety inhibits the pore-forming ability of a naturally-occurring B moiety of said toxin.

22. A method of treating bacterial infection in a mammal, said method comprising administering to said mammal a mutant B moiety of a pore-forming binary A-B toxin or a fragment thereof, wherein said mutant B moiety comprises a mutation that inhibits its pore-forming ability, and wherein said mutant B moiety inhibits the pore-forming ability of a naturally-occurring B moiety of said toxin.

23. The method of claim 9, 10, 21, or 22, wherein said B moiety or said mutant B moiety is anthrax protective antigen and said bacterial infection is an anthrax infection.

24. The method of claim 9, 10, 21, or 22, further comprising administering to said mammal an antibody that binds said naturally-occurring B moiety.

25. The method of claim 9, 10, 21, or 22, wherein said mammal is a human.
26. The method of claim 25, wherein said mammal has been exposed to B. anthracis spores.
27. An purified antibody that specifically binds a naturally-occurring B moiety of a a pore-forming binary A-B toxin with greater affinity than a mutant B moiety of said said toxin, wherein said mutant B moiety comprises a mutation that inhibits its pore-forming ability.
28. The antibody of claim 27, wherein said mutant B moiety inhibits the pore-forming forming ability of a naturally-occurring B moiety of said toxin.

Bacterial toxins that form pores in membranes and for which the agents that inhibit membrane pore formation of the invention would be effective include diphtheria toxin, pseudomonas exotoxin, anthrax toxin, botulinum toxin, tetanus toxin, streptolysin O, aerolysin and S. aureus .alpha.-hemolysin (also called .alpha.-toxin), and the like. These toxins are similar because they all insert into membranes by exposing a hydrophobic site, and they act via a mechanism whereby the toxin enters the cytoplasm of cells to manifest its toxic activity. See, for example, Tobkes et al, Biochemistry 24, 1915-1920 (1985); Menestrina et al. Biophys. J. 60, 1388-1400 (1991); Blaustein et al. Proc.Natl.Acad.Sci. USA 86, 2209-2213 (1989); Hoch et al., Proc.Natl.Acad.Sci. USA 82, 1692-1696 (1985); Lesieur et al. Molecular Membrane Biology 14, 45-64 (1997); Valeva et al. Biochemistry 36, 13298-13304 (1997); London, Molecular Microbiology 6, 3277-3282 (1992); and Bayley, Current Biology 7, R763-R767; which are herein incorporated by reference. Bacterial toxins such as these are susceptible to treatment by the methods of the invention.

Other Reference Publication (23):

Blaustein et al., "Anthrax toxin: Channel-forming activity of protective antigen in planar phospholipid bilayers," Proc. Natl. Acad. Sci. USA, 86:2209-2213 (1989).

CLAIMS:

1. A method for identifying antimicrobial agents which inhibit bacterial toxin membrane pore formation, comprising:

contacting a membrane pore-forming toxin protein with a target agent in the presence of a membrane under conditions in which the toxin protein spontaneously forms pores in the membrane; measuring the extent of pore formation in the membrane; and comparing the extent of membrane pore formation to that obtained in the absence of the target agent, wherein at least 10% inhibition of membrane pore formation by the target agent constitutes identifying an antimicrobial agent.

WEST Search History

DATE: Tuesday, May 18, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=USPT; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L1	anthr\$.ti,clm.	9474
<input type="checkbox"/>	L2	L1 and (protective or pa or pa63 or pa20 or b-moiety or b-moieties or bsubunit or b-subunit or b-fragment or translocation)	2072
<input type="checkbox"/>	L3	L1 and (protective or pa or pa63 or pa20 or b-moiety or b-moieties or bsubunit or b-subunit or b-fragment or translocation or domain or mutation or mutant or mutagenesis or alteration or altered or changes or substitution).clm.	544
<input type="checkbox"/>	L4	L3 and (peptide or protein or proteinaceous or polypeptide or poly-peptide or aminoacid or sequence or seq or amino or recombinant or recombinantly).clm.	200
<input type="checkbox"/>	L5	L4 and anthrax	13
<input type="checkbox"/>	L6	L1 and anthrax	51
<input type="checkbox"/>	L7	L6 and (sitedirected or site-directed or mutation or mutagenesis or mutant or insertion or substitution or d425 or 425 or c-terminal or cooh-terminal or terminal or altered or changed or modified or domain)	38

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 50 of 51 returned.**

-
- ☐ 1. [6730230](#). 11 Jan 02; 04 May 04. Use of high density microparticles for removal of pathogens. Cook; David N., et al. 210/695; 210/222 210/800 252/62.51R 435/261 435/5 435/7.2 435/7.32 436/523 436/526. B03C001/00 G01N033/53 G01N033/569.
-
- ☐ 2. [6729196](#). 01 Feb 01; 04 May 04. Biological individual sampler. Moler; Christopher L., et al. 73/863.22;. G01N031/20.
-
- ☐ 3. [6723890](#). 14 Sep 01; 20 Apr 04. Concentrated formulations and methods for neutralizing chemical and biological toxants. Tucker; Mark D., et al. 588/200; 252/186.41 510/110 510/370 510/372 510/504 516/15 588/218 588/221 588/901. A62D003/00 B01F017/18 B01F017/38 C11D001/62 C11D003/39.
-
- ☐ 4. [6716823](#). 23 Mar 00; 06 Apr 04. Noninvasive genetic immunization, expression products therefrom, and uses thereof. Tang; De-chu C., et al. 514/44; 424/93.21 435/320.1 435/375. A61K031/70 A61K048/00 C12N015/00 C12N005/00.
-
- ☐ 5. [6699433](#). 28 Mar 02; 02 Mar 04. Method of decontamination of whole structures and articles contaminated by pathogenic spores. Weinberg; Mark J., et al. 422/32; 422/4. A61L002/20.
-
- ☐ 6. [6679419](#). 01 Feb 02; 20 Jan 04. Mailbox. Sarracino; Maximo. 232/17; 422/186.3 422/24. B65D091/00.
-
- ☐ 7. [6656919](#). 11 Jan 02; 02 Dec 03. Method and a product for the rapid decontamination and sterilization of bacterial endospores. Baugh; Clarence L., et al. 514/46; 514/2 514/642 514/693 514/724 514/728. A61K031/70 A61K031/14 A61K031/11 A61K031/045.
-
- ☐ 8. [6653519](#). 03 Apr 01; 25 Nov 03. Reactive nanoparticles as destructive adsorbents for biological and chemical contamination. Koper; Olga, et al. 588/200; 422/28 424/489 424/490 424/600 424/617 424/618 424/619 424/635 424/639 424/641 424/646 424/661 424/688 424/718 424/722 424/723. A01N025/00 A01N025/12 A01N059/00.
-
- ☐ 9. [6592872](#). 15 Sep 97; 15 Jul 03. Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein. Klimpel; Kurt, et al. 424/197.11; 424/183.1 424/184.1 424/192.1 424/193.1 424/195.11 424/236.1 424/246.1 514/2 514/885 530/323 530/350 530/402 530/403 530/825. A61K039/07 A61K039/02 C07K014/32 C07K019/00.
-
- ☐ 10. [6588650](#). 13 Nov 01; 08 Jul 03. Anthrax detecting envelope system. Polidori; Anthony. 229/71; 229/120.32 229/72. B65D027/04.
-
- ☐ 11. [6573245](#). 28 Apr 99; 03 Jun 03. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof. Marciani; Dante J.. 514/25; 424/185.1 424/193.1 424/194.1 514/42 514/54 514/55 514/61. A61K031/70 A61K039/00.
-
- ☐ 12. [6569630](#). 15 Oct 01; 27 May 03. Methods and compositions for aptamers against anthrax. Vivekananda; Jeevalatha, et al. 435/6; 435/91.2 536/22.1 536/23.1. C12Q001/68 C12P019/34
-

C07H021/04 C07H021/02.

-
- ☐ 13. 6541001. 21 Aug 00; 01 Apr 03. Vaccine composition and method of using the same. Gallili; Gilad, et al. 424/184.1; 424/204.1 424/214.1 435/5. A61K039/00 A61K039/12 A61K039/17 C12Q001/70.
-
- ☐ 14. 6524846. 05 Nov 01; 25 Feb 03. Biological toxin detection system for mailed materials. Robinson, Jr.; William L.. 435/287.4; 422/86 435/287.7 435/288.7 436/111. C12M001/34.
-
- ☐ 15. 6503906. 21 Feb 02; 07 Jan 03. Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics. Lee; Ren-Jin. 514/253.05; 514/253.07 514/253.08 514/885. A61K031/495.
-
- ☐ 16. 6488900. 19 Oct 99; 03 Dec 02. Method and apparatus for air purification. Call; Charles J., et al. 422/173; 422/120 422/122 422/125 422/174 422/177 422/180. B01D053/34 A62B011/00.
-
- ☐ 17. 6488872. 21 Jul 00; 03 Dec 02. Microfabricated devices and method of manufacturing the same. Beebe; David J., et al. 264/31; 264/139 264/240 264/254 264/255 264/267 264/34 264/35 264/459 264/463 422/50 422/68.1. E04B001/16.
-
- ☐ 18. 6485925. 13 Dec 00; 26 Nov 02. Anthrax lethal factor is a MAPK kinase protease. Duesbery; Nicholas, et al. 435/23; 435/6 435/7.1 435/7.21 435/7.23 536/23.1 536/23.2. C12Q001/37 G01N033/567 G01N033/574 G01N033/53 C07H021/04.
-
- ☐ 19. 6472155. 08 Jun 00; 29 Oct 02. Species specific identification of spore-producing microbes using the gene sequence of small acid-soluble spore coat proteins for amplification based diagnostics. McKinney; Nancy. 435/6; 435/91.1 435/91.2 536/22.1 536/23.1. C12Q001/68.
-
- ☐ 20. 6448016. 12 Jun 01; 10 Sep 02. Nucleotide sequences for detection of Bacillus anthracis. Rastogi; Vipin K., et al. 435/6; 435/91.2 536/23.1 536/23.7 536/24.32 536/24.33. C12Q001/68 C07H021/04 C12P019/34.
-
- ☐ 21. 6440405. 06 Jun 00; 27 Aug 02. Quaternary ammonium functionalized dendrimers and methods of use therefor. Cooper; Stuart L., et al. 424/78.17; 424/486 424/719 424/DIG.16 564/281. A61K031/74 A61K047/48 A61K033/02 C07C211/62.
-
- ☐ 22. 6436933. 26 Mar 01; 20 Aug 02. Inhibitors of anthrax lethal factor activity. Rideout; Darryl, et al. 514/235.8; 514/234.5 514/235.2 514/235.5 514/238.5. A61K031/535.
-
- ☐ 23. 6424864. 19 May 00; 23 Jul 02. Method and apparatus for wave therapy. Matsuura; Masayuki. 607/3; 607/66 607/76. A61N001/32.
-
- ☐ 24. 6420139. 06 Jul 00; 16 Jul 02. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae. Classen; John Barthelow. 435/69.3; 424/184.1 424/201.1 424/202.1 424/203.1 424/212.1 424/217.1. C12N015/109 A61K039/00 A61K039/295 A61K039/116 A61K039/165.
-
- ☐ 25. 6417423. 14 Apr 00; 09 Jul 02. Reactive nanoparticles as destructive adsorbents for biological and chemical contamination. Koper; Olga, et al. 588/200; 422/28 422/37. A62D003/00.
-
- ☐ 26. 6387665. 07 Mar 00; 14 May 02. Method of making a vaccine for anthrax. Ivins; Bruce, et al.
-

435/71.1; 424/184.1 424/234.1 424/246.1 435/252.3 435/252.31 435/320.1 435/485 435/69.1 435/69.4 530/350. C12P021/04.

☐ 27. 6329156. 22 Mar 99; 11 Dec 01. Method for screening inhibitors of the toxicity of *Bacillus anthracis*. Cirino; Nick M., et al. 435/7.21; 435/4 435/6 435/7.2 435/7.32 436/172 436/544 436/546. G01N033/567 G01N033/554 G01N033/532 G01N033/533.

☐ 28. 6316197. 01 Feb 00; 13 Nov 01. Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes. Das; Rina, et al. 435/6; 435/91.2 435/91.5 536/24.31. C12Q001/68 C12P019/34 C07H021/04.

☐ 29. 6316006. 23 Nov 94; 13 Nov 01. Asporogenic *B. anthracis* expression system. Worsham; Patricia, et al. 424/246.1; 435/252.3 435/252.31 435/485. C12N015/00.

☐ 30. 6309633. 19 Jun 99; 30 Oct 01. Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same. Ekwuribe; Nnochiri, et al. 424/85.1; 424/193.1 424/194.1 424/85.2 424/85.4 424/94.3 435/188 514/12 514/2 514/21 514/3 514/476 514/506 514/579 514/613 514/715 514/8 530/303 530/345 530/405 530/406 530/409 530/410 530/411. A61K009/107 A61K038/17 A61K038/28 A61K039/385 C07K001/113.

☐ 31. 6303316. 30 Jun 00; 16 Oct 01. Organic semiconductor recognition complex and system. Kiel; Johnathan L., et al. 435/6; 435/7.1 435/91.2 436/94 536/23.1. C12Q001/68 C12P019/34 C07H021/04.

☐ 32. 6267966. 25 Feb 99; 31 Jul 01. Vaccine production of the *Bacillus anthracis* protective antigen. Baillie; Leslie W J. 424/200.1; 424/184.1 424/235.1 424/236.1 424/93.46 424/93.462 435/252.3 435/252.31 435/320.1 435/480 435/485 435/69.3 530/825 536/23.7. A61K039/295.

☐ 33. 6262029. 13 Aug 99; 17 Jul 01. Chemically modified saponins and the use thereof as adjuvants. Press; Jeffery B., et al. 514/26; 424/184.1 424/204.1 424/234.1 514/23 536/18.6 536/5. A61K031/70 A61K039/00 C07H015/24.

☐ 34. 6080725. 13 Apr 99; 27 Jun 00. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof. Marciani; Dante J.. 514/26; 424/184.1 514/25 536/4.1 536/5. A61K031/705 A61K039/00.

☐ 35. 6022855. 14 Sep 95; 08 Feb 00. Methods and reagents for inhibiting furin endoprotease. Thomas; Gary, et al. 514/12; 530/330 530/350. C07K014/81 C07K004/12 C07K005/10 A61K038/55.

☐ 36. 5874088. 05 Jan 95; 23 Feb 99. Deletion mutants of cholera vaccines expressing heterologous antigens. Mekalanos; John J.. 424/200.1; 424/203.1 424/235.1 424/261.1 435/243 435/252.1 435/252.3 435/69.3 435/909. A61K039/106 C12N001/21.

☐ 37. 5840312. 19 Oct 94; 24 Nov 98. Recombinant *Bacillus anthracis* strains unable to produce the lethal factor protein or edema factor protein. Mock; Michele, et al. 424/200.1; 424/235.1 424/246.1 424/93.46 435/252.31 435/320.1 435/480 435/485 435/69.3 536/23.7. A61K039/07 C12N015/31 C12N015/75 C12N015/70.

☐ 38. 5747028. 07 Jun 95; 05 May 98. Immunizing compositions comprising *Vibrio cholerae* expressing heterologous antigens. Calderwood; Stephen B., et al. 424/93.2; 435/252.3 435/69.1 435/69.3. C12N001/21 A61K039/106.

☐ 39. [5728385](#). 12 Aug 93; 17 Mar 98. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae. Classen; John Barthelow. 424/201.1; 424/184.1 424/202.1 424/203.1 424/212.1 424/217.1 424/218.1 424/219.1 424/224.1 424/227.1 424/228.1 424/230.1 424/233.1 424/234.1 424/244.1 424/245.1 424/246.1 424/247.1 424/249.1 424/254.1 424/258.1 424/261.1. A61K039/02 A61K039/12 A61K039/116 A61K039/295.

☐ 40. [5723283](#). 31 May 95; 03 Mar 98. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae. Classen; John Barthelow. 435/4; 424/184.1 424/204.1 424/234.1. C12Q001/02 A61K039/00 A61K039/02 A61K039/12.

☐ 41. [5677274](#). 25 Jun 93; 14 Oct 97. Anthrax toxin fusion proteins and related methods. Leppla; Stephen H., et al. 514/2; A61K039/00.

☐ 42. [5604201](#). 08 Jan 93; 18 Feb 97. Methods and reagents for inhibiting furin endoprotease. Thomas; Gary, et al. 514/12; 435/252.3 435/254.2 435/320.1 530/350 536/23.5. C07K014/81 C07H021/04 A61K038/55 C12N001/21 C12N001/15 C12N015/63.

☐ 43. [5591631](#). 12 Feb 93; 07 Jan 97. Anthrax toxin fusion proteins, nucleic acid encoding same. Leppla; Stephen H., et al. 435/252.3; 435/320.1 530/350 530/402 536/23.4 536/23.7. C07K019/00 C12N015/31 C12N015/70.

☐ 44. [5057540](#). 27 Aug 90; 15 Oct 91. Saponin adjuvant. Kensil; Charlotte A., et al. 424/278.1; 424/207.1 424/765 424/775 514/25 514/26 514/33 514/35 514/885 536/4.1 536/5 536/6.3. A61K031/70 A61K031/705 A61K039/00.

☐ 45. [4781041](#). 27 Oct 86; 01 Nov 88. Apparatus for cleaning garments and soft goods contaminated with nuclear, chemical and/or biological contaminants. Fowler; David E.. 68/18F; 68/18R 976/DIG.376. D06F043/08.

☐ 46. [4205066](#). 10 Oct 78; 27 May 80. Bait compositions for anthropophilic flies. Hennart; Claude, et al. 424/84; A01N007/14.

☐ 47. [3208909](#). ; 28 Sep 65. Anaerobic process for production of a gel-adsorbed anthrax immunizing antigen. MILTON PUZISS, et al. 435/448; 435/170 435/173.1 435/832.

☐ 48. [2151364](#). ; 21 Mar 39. Anthrax vaccine. WINEGARDEN HOWARD M. 424/246.1; 424/278.1.

☐ 49. [2017606](#). ; 15 Oct 35. Anthrax antigen preparation and product. JOHN REICHEL, et al. 424/246.1; 435/170 435/252.5 435/832.

☐ 50. [1989014](#). ; 22 Jan 35. Anthrax vaccine. MARIO MAZZUCCHI. 424/246.1; 424/278.1 435/832 514/25 514/26.

[Generate Collection](#)[Print](#)

Terms	Documents
-----------------------	---------------------------

L1 and anthrax	51
----------------	----

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results** - Record(s) 1 through 13 of 13 returned.

-
- ☐ 1. [6716823](#). 23 Mar 00; 06 Apr 04. Noninvasive genetic immunization, expression products therefrom, and uses thereof. Tang; De-chu C., et al. 514/44; 424/93.21 435/320.1 435/375. A61K031/70 A61K048/00 C12N015/00 C12N005/00.
-
- ☐ 2. [6592872](#). 15 Sep 97; 15 Jul 03. Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein. Klimpel; Kurt, et al. 424/197.11; 424/183.1 424/184.1 424/192.1 424/193.1 424/195.11 424/236.1 424/246.1 514/2 514/885 530/323 530/350 530/402 530/403 530/825. A61K039/07 A61K039/02 C07K014/32 C07K019/00.
-
- ☐ 3. [6485925](#). 13 Dec 00; 26 Nov 02. Anthrax lethal factor is a MAPK kinase protease. Duesbery; Nicholas, et al. 435/23; 435/6 435/7.1 435/7.21 435/7.23 536/23.1 536/23.2. C12Q001/37 G01N033/567 G01N033/574 G01N033/53 C07H021/04.
-
- ☐ 4. [6387665](#). 07 Mar 00; 14 May 02. Method of making a vaccine for anthrax. Ivins; Bruce, et al. 435/71.1; 424/184.1 424/234.1 424/246.1 435/252.3 435/252.31 435/320.1 435/485 435/69.1 435/69.4 530/350. C12P021/04.
-
- ☐ 5. [6329156](#). 22 Mar 99; 11 Dec 01. Method for screening inhibitors of the toxicity of *Bacillus anthracis*. Cirino; Nick M., et al. 435/7.21; 435/4 435/6 435/7.2 435/7.32 436/172 436/544 436/546. G01N033/567 G01N033/554 G01N033/532 G01N033/533.
-
- ☐ 6. [6303316](#). 30 Jun 00; 16 Oct 01. Organic semiconductor recognition complex and system. Kiel; Johnathan L., et al. 435/6; 435/7.1 435/91.2 436/94 536/23.1. C12Q001/68 C12P019/34 C07H021/04.
-
- ☐ 7. [6267966](#). 25 Feb 99; 31 Jul 01. Vaccine production of the *Bacillus anthracis* protective antigen. Baillie; Leslie W J. 424/200.1; 424/184.1 424/235.1 424/236.1 424/93.46 424/93.462 435/252.3 435/252.31 435/320.1 435/480 435/485 435/69.3 530/825 536/23.7. A61K039/295.
-
- ☐ 8. [6262029](#). 13 Aug 99; 17 Jul 01. Chemically modified saponins and the use thereof as adjuvants. Press; Jeffery B., et al. 514/26; 424/184.1 424/204.1 424/234.1 514/23 536/18.6 536/5. A61K031/70 A61K039/00 C07H015/24.
-
- ☐ 9. [6080725](#). 13 Apr 99; 27 Jun 00. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof. Marciani; Dante J.. 514/26; 424/184.1 514/25 536/4.1 536/5. A61K031/705 A61K039/00.
-
- ☐ 10. [5874088](#). 05 Jan 95; 23 Feb 99. Deletion mutants of cholera vaccines expressing heterologous antigens. Mekalanos; John J.. 424/200.1; 424/203.1 424/235.1 424/261.1 435/243 435/252.1 435/252.3 435/69.3 435/909. A61K039/106 C12N001/21.
-
- ☐ 11. [5840312](#). 19 Oct 94; 24 Nov 98. Recombinant *Bacillus anthracis* strains unable to produce the lethal factor protein or edema factor protein. Mock; Michele, et al. 424/200.1; 424/235.1 424/246.1 424/93.46 435/252.31 435/320.1 435/480 435/485 435/69.3 536/23.7. A61K039/07 C12N015/31 C12N015/75 C12N015/70.
-

☐ 12. 5677274. 25 Jun 93; 14 Oct 97. Anthrax toxin fusion proteins and related methods. Leppla; Stephen H., et al. 514/2;. A61K039/00.

☐ 13. 5591631. 12 Feb 93; 07 Jan 97. Anthrax toxin fusion proteins, nucleic acid encoding same. Leppla; Stephen H., et al. 435/252.3; 435/320.1 530/350 530/402 536/23.4 536/23.7. C07K019/00 C12N015/31 C12N015/70.

[Generate Collection](#)[Print](#)

Terms	Documents
L4 and anthrax	13

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

First Hit Fwd Refs

L5: Entry 1 of 13

File: USPT

Apr 6, 2004

DOCUMENT-IDENTIFIER: US 6716823 B1

TITLE: Noninvasive genetic immunization, expression products therefrom, and uses thereof

Abstract Text (1):

Disclosed and claimed are methods of non-invasive genetic immunization in an animal and/or methods of inducing a systemic immune or therapeutic response in an animal, products therefrom and uses for the methods and products therefrom. The methods can include contacting skin of the animal with a vector in an amount effective to induce the systemic immune or therapeutic response in the animal. The vector can include and express an exogenous nucleic acid molecule encoding an epitope or gene product of interest. The systemic immune response can be to or from the epitope or gene product. The nucleic acid molecule can encode an epitope of interest and/or an antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates an immunological response and/or stimulates and/or modulates expression, e.g., transcription and/or translation, such as transcription and/or translation of an endogenous and/or exogenous nucleic acid molecule; e.g., one or more of influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP; and/or a therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a cytokine gene. The immune response can be induced by the vector expressing the nucleic acid molecule in the animal's cells. The animal's cells can be epidermal cells. The immune response can be against a pathogen or a neoplasm. A prophylactic vaccine or a therapeutic vaccine or an immunological composition can include the vector. The animal can be a vertebrate, e.g., a mammal, such as human, a cow, a horse, a dog, a cat, a goat, a sheep or a pig; or fowl such as turkey, chicken or duck. The vector can be one or more of a viral vector, including viral coat, e.g., with some or all viral genes deleted therefrom, bacterial, protozoan, transposon, retrotransposon, and DNA vector, e.g., a recombinant vector; for instance, an adenovirus, such as an adenovirus defective in its E1 and/or E3 and/or E4 region (s). The method can encompass applying a delivery device including the vector to the skin of the animal, as well as such a method further including disposing the vector in and/or on the delivery device. The vector can have all viral genes deleted therefrom. The vector can induce a therapeutic and/or an anti-tumor effect in the animal, e.g., by expressing an oncogene, a tumor-suppressor gene, or a tumor-associated gene. Immunological products generated by the expression, e.g., antibodies, cells from the methods, and the expression products, are likewise useful in in vitro and ex vivo applications, and such immunological and expression products and cells and applications are disclosed and claimed. Methods for expressing a gene product in vivo and products therefor and therefrom including mucosal and/or intranasal administration of an adenovirus, advantageously an E1 and/or E3 and/or E4 defective or deleted adenovirus, such as a human adenovirus or canine adenovirus, are also disclosed and claimed.

Brief Summary Text (3):

The invention yet further still relates to such methods wherein the nucleic acid molecule can encode an epitope of interest and/or an antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates an immunological response and/or stimulates and/or modulates expression, e.g., transcription and/or

translation, such as transcription and/or translation of an endogenous and/or exogenous nucleic acid molecule. The invention additionally relates to such methods wherein the nucleic acid molecule can be exogenous to the vector. The invention also relates to such methods wherein the exogenous nucleic acid molecule encodes one or more of an antigen or portion thereof, e.g., one or more of an epitope of interest from a pathogen, e.g., an epitope, antigen or gene product which modifies allergic response, an epitope antigen or gene product which modifies physiological function, influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP; and/or a therapeutic or an immunomodulatory gene, a co-stimulatory gene and/or a cytokine gene.

Brief Summary Text (29):

The invention additionally provides such methods wherein the nucleic acid molecule can be exogenous to the vector. The invention also provides such methods wherein the exogenous nucleic acid molecule encodes one or more of an antigen of interest or portion thereof, e.g., an epitope of interest, from a pathogen; for instance, one or more of an epitope of interest from or the antigen comprising influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP; and/or a therapeutic and/or an immunomodulatory gene, such as a co-stimulatory gene and/or a cytokine gene. See also U.S. Pat. No. 5,990,091, WO 99/60164 and WO 98/00166 and documents cited therein.

Detailed Description Text (7):

In another advantageous embodiment, the vector expresses a gene which encodes influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HW gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, mycobacterium tuberculosis HSP or a mutant thereof.

Detailed Description Text (8):

In an embodiment of the invention, the immune response in the animal is induced by genetic vectors expressing genes encoding antigens of interest in the animal's cells. In another embodiment of the invention, the antigen of interest is selected from the group comprising influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP. In another embodiment of the method, the animal's cells are epidermal cells. In another embodiment of the method, the immune response is against a pathogen or a neoplasm. In another embodiment of the method, the genetic vector is used as a prophylactic vaccine or a therapeutic vaccine. In another embodiment of the invention, the genetic vector comprises genetic vectors capable of expressing an antigen of interest in the animal's cells. In a further embodiment of the method, the animal is a vertebrate.

Detailed Description Text (12):

Representative examples of antigens which can be used to produce an immune response using the methods of the present invention include influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP, etc. Most preferably, the immune response produces a protective effect against neoplasms

or infectious pathogens.

CLAIMS:

14. The method of claim 1, wherein the nucleic acid molecule encodes one or more of: of: influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP and malaria pfg.
17. The method of claim 1 wherein the vector comprises a recombinant vector.

First Hit Fwd Refs

L6: Entry 1 of 51

File: USPT

May 4, 2004

US-PAT-NO: 6730230

DOCUMENT-IDENTIFIER: US 6730230 B2

TITLE: Use of high density microparticles for removal of pathogens

DATE-ISSUED: May 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; David N.	Lafayette	CA		
Monroy; Rodney L.	Rockport	MA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Miltenyi Biotec GmbH	Bergisch Gladbach			DE	03

APPL-NO: 10/ 043471 [PALM]

DATE FILED: January 11, 2002

PARENT-CASE:

This application claims the benefit of priority of provisional application Ser. No. 60/262,443, filed Jan. 16, 2001, the contents of which are incorporated herein by reference in their entirety.

INT-CL: [07] B03 C 1/00, G01 N 33/53, G01 N 33/569

US-CL-ISSUED: 210/695, 210/800, 210/222, 252/62.51R, 435/5, 435/7.2, 435/7.32, 435/261, 436/523, 436/526

US-CL-CURRENT: 210/695, 210/222, 210/800, 252/62.51R, 435/261, 435/5, 435/7.2, 435/7.32, 436/523, 436/526

FIELD-OF-SEARCH: 210/695, 210/800, 210/222, 252/62.51R, 435/5, 435/7.2, 435/7.32, 435/261, 436/523, 436/526

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

Clear

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/> <u>3970518</u>	July 1976	Giaever	435/7.32
<input type="checkbox"/> <u>5576185</u>	November 1996	Coulter et al.	210/695

ART-UNIT: 1723

PRIMARY-EXAMINER: Reifsnyder; David A.

ATTY-AGENT-FIRM: Olstein; Elliot M. Stauffer; Raymond E.

ABSTRACT:

Methods of using high-density microparticles to bind and remove pathogens from biological fluids are disclosed. Pathogens include prions, viruses, bacteria and protozoa.

28 Claims, 0 Drawing figures

[First Hit](#) [Fwd Refs](#)

Generate Collection

L7: Entry 37 of 38

File: USPT

Jan 7, 1997

US-PAT-NO: 5591631

DOCUMENT-IDENTIFIER: US 5591631 A

TITLE: Anthrax toxin fusion proteins, nucleic acid encoding same

DATE-ISSUED: January 7, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leppla; Stephen H.	Bethesda	MD		
Klimpel; Kurt R.	Gaithersburg	MD		
Arora; Naveen	Delhi			IN
Singh; Yogendra	Delhi			IN
Nicholls; Peter J.	Welling Kent			GB

US-CL-CURRENT: 435/252.3; 435/320.1, 530/350, 530/402, 536/23.4, 536/23.7

CLAIMS:

What is claimed is:

1. A nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding a polypeptide, wherein said fusion protein lacks the catalytic domain of LF.
2. The nucleic acid of claim 1, wherein the polypeptide is a toxin.
3. The nucleic acid of claim 2, wherein the toxin is Pseudomonas exotoxin A.
4. The nucleic acid of claim 2, wherein the toxin is the A chain of Diphtheria toxin.
5. The nucleic acid of claim 2, wherein the toxin is shiga toxin.
6. The nucleic acid of claim 1, comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:5.
7. The nucleic acid of claim 1, wherein the fusion protein comprises the protein defined in the Sequence Listing as SEQ ID NO:6.
8. A protein encoded by the nucleic acid of claim 1.
9. A vector comprising the nucleic acid of claim 1.

[0020] "Mutation" means an alteration in the nucleic acid sequence such that the amino acid sequence encoded by the nucleic acid sequence has at least one amino acid alteration from a naturally-occurring sequence. The mutation may, without limitation, be an insertion, deletion, frameshift mutation, or missense mutation.

[0033] "Fragment" means polypeptide having a region of consecutive amino acids that is identical to the corresponding region in a PA mutant. The fragment has either a reduced ability to form pores or translocate toxins compared to naturally-occurring PA. The fragment may also inhibit the pore-forming ability of naturally-occurring PA. This decrease in pore formation or toxin translocation is positively correlated with, and could be predicted by, a decrease in activity in the cell surface translocation, LFnDTA toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LFnDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. In one desirable embodiment, the decrease in pore formation or translocation of EF or LF is at least 20% relative to naturally-occurring PA63. More desirably, the decrease is at least 40%, and most desirably, the decrease is at least 80%. The inhibition of the pore-forming ability of naturally-occurring PA is positively correlated with, and could be predicted by, a decrease in activity in an assay described above using an equimolar mixture of naturally-occurring PA and a PA fragment compared to using naturally-occurring PA alone. In one desirable embodiment, the decrease is at least 20, 40, 60, 80, or 99% compared to the activity using only naturally-occurring PA. Desirably, the fragment is immunogenic and induces the production of protective antibodies against naturally-occurring PA. In another desirable embodiment, the administration of the fragment to a mammal, as described in Example 9, prevents or diminishes an anthrax infection for a period of at least 1 month, more desirably 3 months, or most desirably 6 months. Examples of possible fragments include the C-terminal 63 kDA tryptic fragment of a PA mutant or a PA mutant having a deletion of amino acids that form the transmembrane pore.

moiety (moy'ī-tē)

1. Originally, a half; now, loosely, a portion of something.
2. Functional group.

[M.E. *moite*, a half]

Prev

[Home](#)[Help](#)[Subjects](#)[Feedback](#)[Random](#) [Search OMD](#)

moiety

1. Originally, a half; now, loosely, a portion of something.
2. Functional group.

Origin: M.E. Moite, a half

(05 Mar 2000)

Previous: [Mohs](#), [Friedrich](#), [Mohs' micrographic surgery](#), [Mohs scale](#), [mohs surgery](#), [Mohs' surgery](#)
Next: [moira](#), [moire](#), [moire metallique](#), [moire pattern](#), [moire topography](#), [moist](#)

Published at the Dept. of Medical Oncology, [University of Newcastle upon Tyne](#)
© [Copyright 1997-2004](#) - The CancerWEB Project. All Rights Reserved.

Drug Discovery & Development

Presenting The Reed Science Group's Inter

[User Services](#)[Online Exclusives](#)[Magazine](#)[Buyer's Guide](#)[Product Info](#)[Advertisi](#)

Search

Go

[Search Tips](#)

Glossary

35 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search:

Go

☒ Word ☐ Definition ☐ Word & Definition**Moiety** A component part of a complex molecule.

InfoLINK

Go

[About InfoLINK](#)

Imaging Systems



Vivid Detail

BIO-RAD

Current Issue



- Current Iss
- Reader Ser
- Free Subsc


Webcasts

ADME Scre



Recent Web
■ **Protein /**
Archived

Bioscience E



Setting up a reagents or research?

Click here to find products available
Contact a variety of email system and information.

E-Newsletter

Stay up-to-date on drug discovery and development



Sponsored Link

High Throughput Genomics
 Improve Research Productivity. Life Science & Drug Discovery

technologies
 HTS/Automati
 Chemistry/Pha
 Cell-Based Te
 Genomics/Pro

Subscribe



© 2004 Reed Business Information a division of Reed Elsevier Inc. All rig
 Use of this website is subject to its terms of use.
 Privacy Policy

moiety (moi-e-ty) (moi'[schwa]-te) [Fr. *moitié*, from L. *medietas*, *medius*, middle] any equal part; a half; also any part or portion.

Table 6. Mutations in other pore-forming toxins that correspond to the mutations in anthrax PA which are described herein. The residues in the other pore-forming toxins that correspond to the residues that were mutated in PA may also be mutated to any other amino acid.

anthrax PA	<i>C. difficile</i> toxin	<i>C.</i> <i>perfringens</i> toxin	<i>C.</i> <i>spiroforme</i> toxin	<i>C.</i> <i>botulinum</i> toxin	<i>B. cereus</i> toxin
K397A	Q425A	Q424A	Q428A	Q398A	K879A
K397D	Q425D	Q424D	Q428D	Q398D	K879D
K397C	Q425C	Q424C	Q428C	Q398C	K879C
K397Q	Q425Q	Q424Q	Q428Q	Q398Q	K879Q
D425A	D453A	D452A	D456A	D426A	D907A
D425N	D453N	D452N	D456N	D426N	D907N
D425E	D453E	D452E	D456E	D426E	D907E
D425K	D453K	D452K	D456K	D426K	D907K
F427A	F455A	F454A	F458A	F428A	F909A
K397D + D425K	Q425D + D453K	Q424D + D452K	Q428D + D456K	Q398D + D426K	K879D + D907K
K395D + K397D + D425K + D426K	K423D + Q425D + D453K + Q454K	K422D + Q424D + D452K + Q453K	K426D + Q428D + D456K + Q457K	K396D + Q398D + D426K + Q427K	T877D K879D + D907K + D908K
ΔD2L2	Δ340-358	Δ339-357	Δ343-361	Δ307-331	Δ797-816
K397D + D425K + F427A	Q425D + D453K + F455A	Q424D + D452K + F454A	Q428D + D456K + F458A	Q398D + D426K + F428A	K879D + D907K + F909A
F427A + ΔD2L2	F455A + Δ340-358	F454A + Δ339-357	F458A + Δ343-361	F428A + Δ307-331	F909A + Δ797-816
K397D + F427A + ΔD2L2	Q425D + F455A + Δ340-358	Q424D + F454A + Δ339-357	Q428D + F458A + Δ343-361	Q398D + F428A + Δ307-331	K879D + F909A + Δ797-816
K397D + D425K + F427A + ΔD2L2	Q425D + D453K + F455A + Δ340-358	Q424D + D452K + F454A + Δ339-357	Q428D + D456K + F458A + Δ343-361	Q398D + D426K + F428A + Δ307-331	K879D + D907K + F909A + Δ797-816
F427D	F455D	F454D	F458D	F428D	F909D
F427K	F455K	F454K	F458K	F428K	F909K


Alternatively, random mutagenesis may be performed on nucleic acids encoding pore-forming mutants (such as cholesterol dependent cytolysins or hexameric or heptameric toxins related to the Staphylococcal α -toxin) using standard molecular biology methods. The encoded mutant toxins may be expressed and optionally purified using standard methods. The rubidium release assay described herein may be used to identify mutant toxins with a reduced ability to form a transmembrane channel. Additionally, animal models may be used to identify dominant negative toxin mutants that reduce the toxicity of the corresponding wild-type toxin when both the mutant and wild-type toxins are administered to the animal.

Other Embodiments

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

Other embodiments are within the claims.



SEQ 8

